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 Abbrevations  
  
 
APS       Ammonium sulphate 
ATP                                                    Adenosine triphosphate 
AP      alkaline phosphatase 
BSA                                                    Bovine serum albumin 
Bp       Basepair 
°C      degree celsius 
DNA                                                   Desoxynucleotide acid 
cDNA      complementary DNA 
gDNA                                                 genomic desoxynucleotide acid 
G6PD      glucose-6-phosphate dehydrogenase 
EDTA       Ethylendiaminotetraacetic acid 
h      Hour 
Hb      Haemoglobin 
In/del      Insertion/deletion 
Kb      kilo basepair 
MgCl                                                   Magnesium chloride 
Min      Minute 
mm      millimeter 
mRNA      messenger RNA 
ng      nanogram 
PBS      Phosphate buffered saline 
PCR      Polymerase chain reaction 
PdxK                                                   Pyridoxal kinase 
Pf      Plasmodium falciparum 
PL       Pyridoxal 
PN      Pyridoxine 
PM      Pyridoxamine 
PLP      Pyridoxal 5-phosphate 
PVM       parasitophorous vacuole membrane 
PV       parasitophorous vacuole 
RNA       Ribonucleic acid 
RT       Room temperature 
SDS      Dodecylsulfat-Sodium salt 
Vit B6                                                  Vitamin B6 
TAE       Tris/Acetic acid/EDTA 
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 TE       Tris/EDTA 
UV       ultraviolet 
V       Volt 
µ       micro (1 x 10-6) 
µg       microgram 
µl       microliter 
µm      micrometer 
µM       micromolar 
+/+      homozygote insertion 
+/-      heterozygote 
-/-      homozygote deletion 
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Summary 
 
Population studies in humans have long detected the enormous selective pressure 
placed by the malaria parasite on its human host and the fundamental role of host 
genetics factor for the progression of the disease.  The erythrocyte is the major site 
for genetic polymorphisms that offer protection against malaria. Genetic alterations 
that affect erythrocytic metabolic enzymes have been associated with reduced 
susceptibility to malaria. 
The erythrocytic pyridoxal kinase (PdxK) plays an important part in the metabolism of 
vitamin B6 and it has been proposed that genetic polymorphism reducing the activity 
of this enzyme in erythrocytes could also be a trait that offers protection against 
malaria. An early study attempted to correlate the lowered erythrocytic PdxK activity 
with reduced susceptibility to malaria. The genetic basis for the lowered erythrocytic 
PdxK activity has been resolved. An 8 bp insertion in the promoter of the pdxk gene 
leads to a higher activity of the enzyme in erythrocytes.The absence of the 8 bp 
insertion (-/-) leads to a lower activity. 
In my study I investigated if the lowered activity of the erythrocytic Pdxk has an effect 
on the malaria parasite Plasmodium falciparum in an in vitro culture system.  
Employing western blot analysis, I could show that the lowered erythrocytic PdxK 
activity is as a result of lower protein levels of the enzyme in erythrocytes of 
individuals without the 8 bp insertion in the pdxk promoter. I cultured P.falciparum 
blood stages with erythrocytes from individuals homozygous for the insertion event 
(+/+), heterozygotes (+/-) and homozygous for the deletion event (-/-).  I observed 
that the growth of the parasite is impaired when cultured in erythrocytes with lowered 
erythrocytic PdxK activity and that the parasite responds to this trait by an 
upregulation of its own de novo and salvage pathway for vitamin B6. I also developed 
a PCR based method for screening human genomic DNA for the presence or 
absence of the 8 bp insertion in the promoter of the pdxk gene. Screening individuals 
for this polymorphism showed that the absence of the 8 bp insertion which leads to 
the lower erythocytic PdxK activity is more prevalent among Africans as compared to 
Caucasians. My results provide additional evidence for the hypothesis that the 
lowered erythrocytic PdxK activity could indeed be another genetic trait offering 
protection against malaria 
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Zusammenfassung 
 
Studien haben gezeigt, dass der Malaria-Erreger einen starken Selektionsdruck auf 
den menschlichen Wirt ausübt. Genetische Faktoren des menschlichen Wirts spielen 
eine wichtige Rolle im Verlauf der Malaria-Erkrankung. Der Malaria-Erreger infiziert 
und vermehrt sich in den roten Blutkörperchen des Menschen. Genetische 
Polymorphismen, die für ihre schützende Wirkung vor Malaria bekannt sind, kommen 
daher vor allem in den roten Blutkörperchen vor.  
Die Pyridoxal kinase (PdxK) der Erythrozyten spielt eine wichtige Rolle in dem 
Metabolismus  von Vitamin B6. In 1976 wurde bereits versucht den Zusammenhang 
zwischen der niedrigeren Aktivität der erythrozytären PdxK und einer verminderten 
Anfälligkeit für Malaria herzustellen. Mittlerweile ist der genetische Hintergrund für die 
niedrigere Aktivität der PdxK in Erythrozyten bekannt. Es konnte gezeigt werden, 
dass  eine 8 bp Insertion im Promoter des pdxk Gens zu einer höheren Aktivität des 
Enzyms in den roten Blutkörperchen führt. Bei Abwesenheit dieser 8 bp Insertion 
hingegen ist die Aktivität von PdxK verringert.  
In meiner Doktorarbeit untersuchte ich, ob die niedrige PdxK Aktivität einen Einfluss 
auf dem Malaria-Erreger, Plasmodium falciparum, in vitro hat.  
Meine Daten haben gezeigt, dass Individuen ohne die 8 bp Insertion im Promoter 
des pdxk Gens, in ihren Erythrozyten eine geringere Menge des Proteins vorhanden 
ist und dadurch auch eine niedrigere Aktivität des Enzyms aufweisen. Ich habe 
darüber hinaus beobachtet, dass das Wachstum des Parasiten gehemmt ist, wenn er 
in Erythrozyten von Individuen mit einer niedrigen PdxK Aktivität kultiviert wird. Der 
Parasit reagiert auf dieses genetische Merkmal mit einer Hochregulierung der 
eigenen Enzyme für die Erhaltung des Vitamin B6 Haushalts. Meine Daten haben 
auch gezeigt, dass die Abwesenheit des 8 bp Insertion in dem pdxk Promoter, die zu 
einer niedrigeren PdxK Aktivität führt, häufiger bei Afrikaner als bei Europäer auftritt.  
Meine Ergebnisse weisen darauf hin, dass die niedrigere PdxK-Aktivität in 
Erythrozyten ein genetisches Merkmal ist, das wahrscheinlich gegen Malaria 
schützen kann. 
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1 Introduction 
 
1.1 Malaria in the past and present 
 
Malaria is, and has always been, a major plague of mankind. Malaria is an ancient 
disease and references to this disease occur in historical documents from China as 
early as about 2700 BC and from Mesopotamia about 2000 BC. Egyptian papyri from 
1570 BC and Hindu texts as far back as the sixth century BC mention a disease that 
is most certainly malaria. In ancient Greek, Hippocrates was the first to describe the 
manifestations of the disease and relate them to the time of year and to the marshy 
places where people lived. In the 18 century the people related these typical fevers to 
the foul air near swamps and therefore it was widely named as malaria from the 
Italian “mala aria” 
In 1880 the army physician A. Laveran (1845-1922) first described malaria parasites 
in human blood.  With the accidental discovery of a methylene blueeosin 
stain by D. L  Romanowsky in 1891, the parasites could be stained in blood smears 
and this facilitated the search for other malaria parasites in birds, reptiles and 
mammals. Over the centuries, circumstantial evidence had accumulated that 
suggested that mosquitoes might somehow be connected with malaria and by 1883 
the American physician, Albert King, had assembled the mass of evidence that was 
to become known as the mosquito-malaria doctrine. In 1884 Sir Patrick Manson 
proposed a transmission from person to person by mosquitoes. He had earlier shown 
that the parasite of filariasis was taken up by female mosquitoes during their blood 
meal, and that the parasites continued their development in the abdomen of the 
mosquito. He considered that this could as well be the case for the malaria parasite 
and his idea was supported by Sir Ronald Ross. Ross who was working in India 
found the pigmented cysts on the stomach wall of the Anopheles mosquito in 1897. A 
year later Ross worked out the complete life cycle of bird malaria and was able to 
show that the route of infection was via the bite of an infected mosquito. 
The life cycle of the parasite in humans remained incompletely understood and 
exoerythrocytic development of the parasite remained a mystery. In 1898, 
MacCullum observed developmental stages of P. relictum in the liver and spleen of 
infected birds. The question of the exoerythrocytic development of the human malaria 
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parasite however remained unresolved until 1947 when H. Shortt and C. Garnham 
showed that a phase of division in the liver preceded the development of parasites in 
the blood (Cox 2010). 
  In 1900, the area of human malaria risk was about 53% of the earth’s land surface. 
From the middle Ages until last century parts of Europe and North America were 
endemic areas. Malaria in the more northern parts of Europe had begun to decline in 
the last century. Denmark and Sweden became free of malaria transmission in the 
1920s and 1930s whereas countries in southern Europe, Italy, Turkey and Greece 
were freed of malaria transmission in the 1960s. The percentage of the global 
population at risk has decreased from 77% at the turn of the 20th century to as low 
as 48% in 2002.  
  Today, malaria remains in poor areas of the world with climate suitable for its 
transmission. More than 120 Plasmodium species have been identified of which P. 
falciparum, P. vivax, P. knowlesi, P. ovale and P. malariae are able to infect human 
hosts. 2.2 billion People are exposed to the threat of P. falciparum malaria which is 
the most lethal form of this disease. With 70% and 25%, most clinical events 
attributed to P .falciparum are found in Africa and in South East Asia (Snow, Guerra 
et al. 2005). Between 700,000 and 2.5 million persons die yearly from malaria, over 
75% of them are children in Sub-Saharan Africa (Breman 2001). Figure 1.1 shows 
the global distribution of P. falciparum malaria today. 
  The health- and socio-economic impact of P. falciparum malaria is highest in Sub-
Saharan Africa. Malaria is also strongly associated with poverty. Taking into 
consideration factors such as tropical location, colonial history, and geographical 
isolation, it has been shown that countries with intensive malaria had income levels of 
only 33% of that of countries without malaria, whether or not the countries were in 
Africa. The impact of malaria on the economic growth of countries is large. The loss 
in growth of countries with endemic malaria is estimated to be as high as 1.3% per 
year and the annual loss in productivity in Africa due to malaria is calculated to be up 
to 12 billion US$ (Gallup and Sachs 2001; Samba 2001). 
In the on-going fight against malaria, an important event took place in April 2000, 
when a large numbers of African leaders gathered to attend the “Summit on malaria” 
and discussed ways to fight malaria and thereby ease the physical and economic 
suffering of its people (Samba 2001). 
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Figure 1.1: The spatial distribution of P. falciparum malaria endemicity  
The global distribution of the annual P. falciparum parasite rates (PfPR) in children from 2-10 
years (yellow to red, 0%–100%) is shown. The rest of the land area was defined as unstable 
risk (dark grey) (Hay, Guerra et al. 2009). 
 
 
 
 
   
1.2 The malaria parasite and its life cycle 
 
Malaria parasites are protozoa of the genus Plasmodium. Genealogically they are 
organized in the phylum of Apicomplexa, suborder of Haemosporidiae and family of 
Plasmodiiae. The malaria parasites are transmitted by the female Anopheles 
mosquito and possess a very complex life cycle. The natural ecology of malaria 
involves the malaria parasites infecting successfully two different hosts, humans and 
the female Anopheles mosquito. The parasite must therefore adapt to very different 
environmental and host specific conditions such as cellular metabolism, temperature 
etc. All Plasmodium species have a common ancestor which evolved as early as 130 
million years ago with a two host life cycle in Dipterans and vertebrates suggesting a 
strong co-evolution of the parasite and its host (Carter and Mendis 2002). 
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The complex life cycle of the parasite includes three stages of two distinct 
proliferation forms with massive intracellular asexual multiplication, the sporogony 
(mosquito midgut) and schizogony (liver and blood). 
During a blood meal, a malaria infected female Anopheles mosquito inoculates the 
parasite in its sporozoite form into the skin of the human host. The sporozoites 
migrate in the skin of individuals, eventually enter the blood stream and travel to the 
liver. Sporozoites enter the liver sinusoids either via the hepatic arteriole or the portal 
venule. Kupffer cells are the resident macrophages of the liver and are strategically 
positioned on the sinusoidal lumen of the liver. Sporozoites actively invade these 
cells, safely transverse them before finally invading hepatocytes (Frevert 2004). 
During invasion the parasitophorous vacuole membrane (PVM) forms around the 
sporozoite. The liver stage undergoes nuclear replication and matures to hepatic 
schizonts followed by the release of tens of thousands of merozoites into the blood 
stream (Amino, Thiberge et al. 2006; Vaughan, Aly et al. 2008). The liver stage 
infection in P. falciparum takes a period of seven days (VanBuskirk, O'Neill et al. 
2009). Intensive studies on the development of the parasites in hepatocytes have 
been carried out on the rodent malaria model. It has been shown that in the case of 
the rodent malaria, Plasmodium berghei merozoites are released directly into the 
bloodstream. The parasite induces the death and detachment of their host 
hepatocytes, followed by the budding of parasite-filled vesicles (merosomes) into the 
sinusoid lumen of the liver (Sturm, Amino et al. 2006). 
In the case of P. vivax and P. ovale, some of the sporozoites entering hepatocytes 
(the proportions vary, depending on the strain) do not develop into exo-erythrocytic 
schizonts directly, but instead form hypnozoites. These small parasite forms (4-5 µm 
in diameter) can remain dormant in the liver for years. At a given point in time, 
although the triggering signal is still unknown, the hypnozoites develop into exo-
erythrocytic schizonts, producing thousands of merozoites, thereby causing relapses 
of the disease (Gilles and Warrel 1993). 
Merozoites released into the bloodstream, invade erythrocytes und become enclosed 
in a parasitophorous vacuole, thus beginning the asexual blood stage of the life 
cycle. In the erythrocytes the parasite undergoes another asexual reproduction, the 
erythrocytic schizogony. The first stage of the intraerythrocytic development is the 
ring stage, which is followed by the metabolically very active trophozoite stage. 
Parasite development is finally completed with the fully developed schizont stage 
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harbouring 16 – 32 daughter merozoites (Gilles and Warrel 1993). The length of the 
intraerythrocytic cycle differs between different Plasmodium species and strains, 
typically 48 hours (P. falciparum, vivax and ovale) or 72 hours (P. malariae), which 
explains the periodicity of the fever paroxysms experienced by the patient. Upon 
primary rupture of the parasitophorous vacuole followed by rupture of the erythrocyte 
membrane, the merozoites are released into the blood stream where they invade 
new erythrocytes (Wickham, Culvenor et al. 2003). 
A few merozoites do not develop into schizont but mature to sexually differentiated 
gametocytes.  When an Anopheles mosquito ingests blood from an infected person, 
the red blood cells infected with asexual parasites are digested with the uninfected, 
but it is the only gametocytes, which undergo further development. The gametocytes 
differentiate into male microgametes and the female macrogamete within the midgut 
lumen of the mosquito. The male microgametes fertilize the female macrogamete 
and the zygote develops into an ookinet, which penetrates the midgut epithelium and 
forms an oocyst on the basal membrane. After rupture of the mature oocyst more 
than 1,000 sporozoites are released and some invade the mosquito’s salivary glands 
via the haemolymph to be injected into a new human host when the female mosquito 
feeds again (Han, Thompson et al. 2000). 
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Figure 1.2: Life cycle of the malaria parasite.  Details described in text at 
www.dpd.cdc.gov 
   
 
 
 
 
1.3 Clinical aspects of malaria 
 
The clinical manifestations of malaria vary with geography, epidemiology, immunity 
and age. In the highly endemic regions of Africa, malaria-attributable death rates 
have been reported as high as 25–30 percent for children. Another group highly at 
risk are pregnant women, who are at risk of delivering low birth newborns. 
Malaria is an acute febrile illness and the severity of disease outcome depends on 
factors attributed to both the parasite and its host. The emergence of natural 
acquired immunity (NAI) against malaria is a slow process in which factors like 
exposure, age and intervention play a vital role. The severity outcome of the disease 
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depends largely on the transmission dynamics in endemic areas. In regions where 
endemic transmission is low, severe malaria occurs mostly among children but also 
adults are susceptible. In areas of stable transmission older children and adults 
develop partial immunity after repeated infections and are at relatively low risk for 
severe disease (Baird, Masbar et al. 1998; Breman 2001; Doolan, Dobano et al. 
2009). 
  The first clinical sign of malaria is fever followed by febrile paroxysms. 2 to 3 days 
before the first paroxysm patients often complain of malaise, headache, dizziness, 
fatigue, pain, anorexia and nausea. The paroxysms are divided into three stages: the 
cold stage (shivering), the hot stage (fever) and the sweating stage with subsequent 
declining fever. The paroxysms periods repeat every 48 or 72 hours in dependence 
of the Plasmodium species. Due to these patterns malaria was given its other names: 
Benign tertian malaria (P. vivax), malignant tertian (P. falciparum), tertian (P. vivax, 
P. ovale) and quartana malaria  (P. malaria). It only occurs with a synchronized 
parasite population in the patient. In P. falciparum malaria the periodicity is often not 
clearly defined resulting in continuous or remittent fever in patients. 
The majority of malaria cases present as these febrile episodes that can be easily 
terminated either by anti-malarial treatment or finally by host responses. However a 
minority of cases of about 1% progress to a life threatening form of disease which is 
referred to as severe or complicated malaria. The development of severe malaria is 
caused by adhesion and sequestration of parasites in the vasculature, release of 
bioactive molecules as well as host immune responses. Severe malaria is a multi 
complex disorder which features as cerebral malaria, severe anaemia, metabolic 
acidosis, hypoglycaemia, renal failure, respiratory distress, hepatic dysfunction, 
circulatory collapse and coma (Miller, Good et al. 1994; Mackintosh, Beeson et al. 
2004; Kirchgatter and Del Portillo 2005). 
Pregnant women comprise the main adult risk group of malaria. The outcome of 
malaria in pregnancy is severe maternal anaemia, low birth weight and fetal loss 
(Mackintosh, Beeson et al. 2004). Pregnancy associated malaria is frequent in first 
time pregnancies and the risk declines with following pregnancies (Salanti, Dahlback 
et al. 2004).  
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1.4 Host genetics and malaria 
 
The malaria parasite and its human host have been closely linked for over a million 
years (Carter and Mendis 2002). The Plasmodium parasite successfully infects and 
replicates in both its human and insect host. During its whole life cycle, the parasite 
depends on specific interactions with the host for to gain access to nutrients, to 
overcome physical barriers and to avoid immune responses. Today, the parasite is 
highly adapted to its host and an expert in survival. Studies on human populations in 
endemic regions show that the parasite exerts enormous selective pressure on its 
human host, revealing the trails of coevolution. Until now, several human 
genetic traits have been identified that affect susceptibility to and/ or pathogenesis of 
P. falciparum malaria and these traits are widely distributed in regions where malaria 
is endemic (Cooke and Hill 2001). 
  Any inherited genetic variant, that affects the replication of the parasites in its 
human host (erythrocytes, hepatocytes), in the mosquito midgut and/or alters the 
recognition of the parasite by the host immune system, has as a great impact on the 
outcome of the disease (Bongfen, Laroque et al. 2009). Figure 1.3 show different 
host factors that interact with the parasite during its life cycle which when genetically 
altered lead to protection against the disease. 
  In the human host the erythrocyte is the major site of parasite infection and 
replication and is therefore the main spot for genetic alterations affecting erythrocytic 
proteins and enzymes that confer resistance against malaria (Min-Oo and Gros 
2005). The best described example for genetic polymorphisms affecting the 
erythrocyte are the haemoglobinopathies (Roberts and Williams 2003; Richer and 
Chudley 2005). The most common haemoglobinopathies are the α- and β- 
thalassaemia where there is a deficient synthesis of the globin protein and three 
structural mutations of the β-globin chain, haemoglobin S HbS (β6 Glu → Val), 
Haemoglobin C HbC (β6 Glu → Lysin), haemoglobin E HbE (β26 Glu → Lys).  
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Figure 1.3: Genetic interactions between host and parasite during the malaria life 
cycle. Both human and mosquito have evolved a series of genetic mechanisms that offer 
protection against Plasmodium parasite infection. Bongfen et al., 2009 
 
 
 
 
The haemoglonopathies are widely distributed in malarious regions of the world. 
Figure 1.4 shows the global distribution of erythrocytes polymorphism. 
 HbS reaches its highest frequencies in tropical and sub-tropical Africa, Saudi Arabia 
and India, HbC is very frequent in West Africa, HbE in Southeast Asia, β 
thalassaemia in the Mediterranean and Asia and α thalassaemia in India (Flint, 
Harding et al. 1993). 
The advantage of the HbS gene against fatal malaria is due to its heterozygote state 
HbAS. The sickle cell disease which is caused by the homozygous state of the sickle 
gene (HbSS) is lethal in early childhood. The protective effect of the HbAS trait has 
been intensively studied. It has been shown that HbAS trait offer protection against 
all causes of mortality, severe malaria anaemia and high density parasitemia. The 
HbAS trait contributes to a 90% reduced risk of severe malaria (Aidoo, Terlouw et al. 
2002; Williams, Mwangi et al. 2005). 
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Figure 1.4:  Global distribution of malaria and red blood cell disorders. Green indicates 
areas where malaria is only present in a few remote locations, yellow indicates areas with 
intermediate malaria risk and red indicates areas with high malaria risk. The hatched area 
shows the distribution of red-blood-cell disorders. Cooke et al., 2001 
 
 
  The HbC and HbE trait have also been shown to have an influence on malaria. 
These genetic traits are known to have only very mild clinical effects in their 
homozygous state. Case control studies have shown that HbC is associated with a 
29% reduction in risk of clinical malaria in HbAC heterozygotes and with a 93% 
reduction in risk in HbCC homozygotes. A homozygous advantage for HbC is 
consistent with observations from a smaller study which reported no episodes of 
severe malaria in HbCC subjects (Modiano, Luoni et al. 2001; Mockenhaupt, 
Ehrhardt et al. 2004). HbE  has been shown to protect against high levels of 
parasitemia which is associated with severe malaria (Chotivanich, Udomsangpetch et 
al. 2002). 
The protective mechanism of the thalassaemia trait for malaria remains unclear. 
Although this trait has no effect on parasite densities, studies have provided sufficient 
evidence to show its protective effect against severe malaria (Williams, Maitland et al. 
1996; Mockenhaupt, Ehrhardt et al. 2004; Williams, Mwangi et al. 2005; Williams, 
Wambua et al. 2005). 
    Erythrocyte polymorphisms that affect the invasion of the parasite have been 
shown to have an impact on malaria.  These red blood cell variants include the Duffy 
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negativity and the Gerbich erythrocyte variant. The invasion pathway of Plasmodium 
vivax involves the Duffy antigen on the surface of the erythrocyte. The absence of its 
expression in the Duffy negative blood group leads to complete resistance to P. vivax 
invasion. P. vivax malaria is therefore nearly absent in Sub-Saharan African where 
the Duffy negative blood group is close to fixation (Miller, Mason et al. 1975; Miller, 
Mason et al. 1976; Langhi and Bordin 2006). A family of glycophorin (GYP) proteins 
(GYPA, GYPB, and GYPC) binds to Plasmodium erythrocyte binding antigen (EBA) 
175 (GYPA/B) and EBA140 (GYPC) and are required for invasion by P. falciparum. 
It has been shown that the GYPC-non expressing Gerbich-negative blood group 
found in malaria-endemic coastal areas of Papua New Guinea [PNG] (45% 
frequency) shows reduced invasion of erythrocytes by P. falciparum (Maier, 
Duraisingh et al. 2003). 
  One genetic polymorphism that affects the cytoskeleton of the erythrocyte is the 
Melanesian ovalocytosis. This occurs due a mutation in the band 3 protein (an anion 
exchanger) of the red blood cell and is lethal in a homozygous state. Case control 
studies have shown that this polymorphism is highly protective against severe 
malaria (Genton, al-Yaman et al. 1995; Allen, O'Donnell et al. 1999). 
 
 
1.4.1 Erythrocytic enzymopathies and their influence on malaria 
  Today a number of genetic polymorphisms are known that affect enzymes of the 
erythrocytic metabolism. These enzymopathies have been shown to have malaria 
protective effect. The most common of these enyzymopathies is the glucose -6-
phosphate dehyrogenase (G6PD) deficiency. The geographical distribution of G6PD 
deficiency and its high frequency in areas which are holo-endemic for malaria, 
suggest that it is protective against P. falciparum malaria. The G6PD deficiency is an 
X chromosome linked disorder and approximately 400 variants are reported. The 
highest prevalence rate are found in tropical Africa and tropical/ subtropical Asia and 
have been shown to protect against severe malaria (Gilles, Fletcher et al. 1967; Roth, 
Raventos-Suarez et al. 1983; Ruwende, Khoo et al. 1995; Guindo, Fairhurst et al. 
2007). 
  Recent in vitro studies have shown that erythrocytic pyruvate kinase deficiency also 
protects against malaria. The protective mechanism was associated with lower 
replication rates of P. falciparum in erythrocytes bearing the deficient pyruvate kinase  
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and enhanced phagocytosis by macrophages (Min-Oo, Fortin et al. 2003; Ayi, Min-
Oo et al. 2008) 
  Another current in vitro study revealed that deficiency of the erythrocytic glutathione 
reductase (GR) also protects against malaria. It was shown that GR deficiency of red 
blood cells however had no effect on the replication rates of the parasites but 
increased the rate of phagocytosis of infected erythrocytes by macrophages  (Gallo, 
Schwarzer et al. 2009). 
 
The human inducible nitric oxide synthase (iNOS) is another enzyme that has been 
proposed to be genetically altered due to the selective pressure of malaria. This 
enzyme is not associated with the erythrocyte but is found in the peripheral blood 
mononucleated cells (PBMC). The iNOS generates nitric oxide, which is a free 
radical with antiparasitic properties (Balmer, Phillips et al. 2000). iNOS is a product of 
the NOS2A  gene and several polymorphic variants of the gene are present. The 
NSO2A-954C allele of this gene has been shown to protect against severe malaria 
(Kun, Mordmuller et al. 1998). However there are human population studies that 
provide contradictory evidence illustrating no association between polymorphisms of 
the iNOS and malaria (Levesque, Hobbs et al. 1999). 
 
 An overview of various host factors associated to malaria and their characteristics 
are listed in table 1 
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1.5  Vitamins and their influence on malaria 
 
Vitamins are essential nutrients and are usually required in small amounts. Vitamins 
are classified as either water soluble or fat soluble. In humans there are 13 vitamins, 
4 fat soluble (A,D, E and K) and 9 water soluble ( 8 B vitamins and vitamin C). 
Vitamins have diverse biochemical functions. Some have hormone-like functions as 
regulators of mineral metabolism (e.g. vitamin D), or regulators of cell and tissue 
growth and differentiation (e.g. some forms of vitamin A). Others function as 
antioxidants (e.g. vitamin E and sometimes vitamin C). The largest number of 
vitamins (e.g. B complex vitamins) functions as precursors for enzyme cofactors, 
which help enzymes in their work as catalysts in metabolism. 
  Today it is clear that nutrition strongly influences the disease burden of malaria. 
However, the relationship between malaria and nutritional status remains complex. It 
has been shown that clinical manifestations and mortality from malaria is more 
severe in malnourished children (Shankar 2000; Caulfield, Richard et al. 2004; 
Ehrhardt, Burchard et al. 2006; Muller and Kappes 2007). 
In this perspective, some vitamins have demonstrated to play an important role. 
Vitamin A is essential for normal immune function (Semba 1998). Several studies 
suggest that it could play a role in potentiating resistance to malaria.  It has been 
shown that vitamin A supplementation can enhance host resistance to malaria 
leading to a reduction in P.falciparum febrile episodes and lower parasite densities 
(Shankar, Genton et al. 1999; Serghides and Kain 2002; Muller and Kappes 2007). 
Riboflavin also known as vitamin B2 has an influence on malaria morbidity.  It has 
been demonstrated that riboflavin deficiency confers a certain degree of protection 
against malaria (Thurnham, Oppenheimer et al. 1983; Dutta, Pinto et al. 1985; Das, 
Das et al. 1988). Riboflavin is an essential factor for the glutathione reductase which 
is an antioxidative enzyme and it has been proposed that deficiency promotes an 
oxidative environment in the erythrocyte which is not conducive for the parasite’s 
survival (Barraviera, Machado et al. 1988; Das, Thurnham et al. 1990). On the other 
hand recent in vitro studies have shown that a high dose of riboflavin suppresses the 
growth of the parasite by preventing the oxidation of haemoglobin which is required 
for its digestion by the parasite (Akompong, Ghori et al. 2000). This finding is in 
paradox to previous studies that have shown riboflavin deficiency protects against 
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malaria and highlights the complex mechanisms in which nutrients can affect malaria 
parasites and the outcome of the disease. 
  Several studies on human and rodent malaria have shown that deficiency of Vitamin 
E tend to protect against malaria. Vitamin E is an antioxidant and its deficiency could 
make the parasite more vulnerable to oxygen radicals in the erythrocyte (Eaton, 
Eckman et al. 1976; Eckman, Eaton et al. 1976; Levander, Ager et al. 1989; Davis, 
Binh et al. 1994). 
The role of B vitamins other than B2 on the severity of malaria is not clear. It has 
been shown thiamine (Vitamin B1) deficiency in individuals can complicate P. 
falciparum malaria suggesting that deficiency in thiamine is associated with greater 
risk of severe malaria (Krishna, Taylor et al. 1999).  
  In summary, the precise role of vitamins on the outcome of a malaria infection is not 
always very clear. Moreover, the deficiency of some vitamins reduces the risk of 
malaria infection while other vitamins are required in sufficient amount to reduce 
malaria infection. 
 
 
 
 
 
1.6 Vitamin B6, function and metabolism 
 
Vitamin B6 is a water soluble vitamin and is a collective term for pyridoxal, 
pyridoxamine and pyridoxine and their respective phosphate easters. Pyridoxal (PL), 
pyridoxine (PN) and pyridoxamine (PM) are phosphorylated by the pyridoxal kinase 
(PdxK) to their phosphate ester derivates with ATP being the phosphate donor. The 
phosphate easter derivate pyridoxal 5-phosphate (PLP) is the principle coenzyme 
form and plays a vital role in the function of more than 100 enzymes that catalyze 
essential chemical reactions in the human body. The majority of enzymes dependent 
on PLP are involved in the metabolism of amino acids. These enzymes are usually 
aminotransferases  and aminodecarboxylases (Alexander, Sandmeier et al. 1994). 
PLP also functions as a co-enzyme for glycogen phosphorylase which is an enzyme 
that catalyzes the release of glucose from stored glycogen. PLP is usually found 
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bound to glycogen in muscles (Vul'fson 1986; Chang, Scott et al. 1987). PLP is also 
an important co-enzyme in reactions involved in the release of glucose from amino 
acids, a process known as gluconeogenesis (Leklem and Shultz 1983). 
In the human brain, the synthesis of neurotransmitters such as dopamin, serotonin 
and histamin are carried out by enzymes dependent on PLP. Failure to maintain the 
right level of PLP can lead to neurological disorders such as epileptic 
encephalopathy (Waymire, Mahuren et al. 1995; Mills, Surtees et al. 2005). PLP also 
plays a vital role in the synthesis of haemoglobin in reticulocytes.  The enzyme δ-
aminolaevulinic acid synthase is dependent on PLP and involved in the synthesis of  
the haeme precursor δ-aminolaevulinic acid. The X-linked siederoblastic anaemia is 
a disease which is due to a deficient variant of the δ-aminolaevelinic acid synthase 
and results in insufficient synthesis of the globin chains. It has been shown that 90% 
of sideroblastic anaemia cases respond positiviely to PLP treatment (Clayton 2006; 
Hunter and Ferreira 2009).  
There have been studies showing the effect of PLP on hormone function. PLP binds 
to steroid receptors in a manner that inhibits the binding of steroid hormones, thus 
decreasing their effects (Cake, DiSorbo et al. 1978; Muldoon and Cidlowski 1980; 
Tully, Allgood et al. 1994).  
Deficiency in vitamin B6 has been associated with weak immune responses 
characterized by impaired interleukin 2 production and lymphocyte proliferation in 
adults (Talbott, Miller et al. 1987; Meydani, Ribaya-Mercado et al. 1991). 
 
 
 
 
1.6.1 Metabolism of vitamin B6 in humans 
Vitamin B6 exists as pyridoxine, pyridoxamine and pyridoxal as well as their 
phosphorylated forms in food. Certain plant food contain a unique form of vitamin B6 
called pyridoxine glucoside. The phosphorylated forms pyridoxal 5-phosphate (PLP), 
pyridoxine 5-phosphate (PNP) and pyridoxamine 5-phosphate (PMP) are 
dephosphorylated in the intestines by an intestinal alkaline phosphatase before 
absorption (Hamm, Mehansho et al. 1979; Mehansho, Hamm et al. 1979). PN, PM 
and PL are absorbed by passive diffusion and enter the circulation. They are rapidly 
taken up in the liver by passive diffusion where they are phosphorylated by the 
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pyridoxal kinase. PMP and PNP are converted to PLP by the PMP- and PNP oxidase 
respectively. PLP is then bound to apo-proteins and transported to the blood or 
dephosphorylated by alkaline phosphotase (AP) (Merrill, Henderson et al. 1984). 
Although other tissues contribute to the metabolism of vitamin B6, the liver is thought 
to be responsible for the PLP found in plasma (Lumeng, Lui et al. 1980). It has been 
shown that PLP binds more tightly to serum albumin than pyridoxal.  When bound to 
proteins, PLP cannot be hydrolysed by phosphatases and is therefore not readily 
available to cells. It has been proposed that pyridoxal released from the liver into the 
bloodstream is the major source of vitamin B6 for tissues (Leklem J et al., 1991) 
  The erythrocyte contains the required enzymes to convert all three forms of vitamin 
B6 (PL, PN and PM) to the active coenzyme PLP.  Pyridoxal, pyridoxine and 
pyridoxamine are rapidly taken up by the erythrocytes via passive diffusion and 
converted to their phosphorylated forms by the pyridoxal kinase. PNP and PMP have 
to be converted to PLP by an oxidase. PLP, PNP and PMP can be metabolized to 
their non phosphorylated forms by alkaline phosphotase and then exit the cell 
(Mehansho and Henderson 1980; Ink and Henderson 1984; Anderson, Perry et al. 
1989). 
In erythrocytes PLP binds tightly to the β globin chain of haemoglobin. Pyridoxal also 
binds to the α globin chain of haemoglobin but not as tightly as PLP. The binding of 
PLP and PL to haemoglobin affects the oxygen affinity. PLP binding to hemoglobin 
decreases the oxygen affinity of haemoglobin, whereas PL binding results in an 
increase on oxygen affinity (Benesch, Yung et al. 1973; Ink and Henderson 1984; 
Natta and Reynolds 1984). 
 
 
 
1.6.2   Metabolism of vitamin B6 in the malaria parasite 
Humans need to take up vitamin B6 through their diet. Other organisms such as 
plants, bacteria and fungi are capable of synthesizing this vitamin de novo 
(Tambasco-Studart, Titiz et al. 2005; Fitzpatrick, Amrhein et al. 2007). It has also 
been confirmed that the malaria parasite P. falciparum possesses a functional de 
novo synthesis pathway for vitamin B6. The parasite synthesizes PLP employing the 
two proteins Pdx1 and Pdx2. It has been shown that Pdx1 and Pdx2 form a complex 
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that functions as a glutamine amidotransferase with Pdx2 as the glutaminase and 
Pdx1 as pyridoxal 5-phosphate synthase domain.  Ribose 5-phosphate and ribulose 
5-phosphate, as well as glyceraldehyde 3-phosphate (G3P) and dihydroxyacetone 
phosphate (DHAP) are substrates for the plasmodial PLP synthase.  In vitro studies 
have shown that glutamine and ammonium sulphate can serve as ammonium donor 
for the PLP synthase (Gengenbacher, Fitzpatrick et al. 2006)  
There is also evidence that P. falciparum has a pyridoxal kinase  that is required for 
the phosphorylation  of vitamin B6 upon uptake and for the parasitic salvage pathway 
of vitamin B6 (Wrenger, Eschbach et al. 2005). The parasite also possesses 
phosphatases (Muller, Knockel et al.; Bozdech, Zhu et al. 2003). It is therefore likely 
that PLP can also be dephosphorylated to PL which could then exit the parasite 
(Muller, Hyde et al.). Homologues of the human pyridoxine 5-phosphate and 
pyridoxamine 5-phosphate oxidase have so far not been found in the parasite 
suggesting that the parasite is not capable of converting the phosphorylated forms of 
pyridoxine and pyridoxamine to PLP.   
Since a de novo synthesis pathway for vitamin B6 is absent in the human host, the 
parasite specific biosythesis pathway for this vitamin has been considered a powerful 
potential drug target (Muller, Hyde et al.; Muller and Kappes 2007) 
Figure 1.5 shows a model illustrating a potential cross talk between the parasite and 
the erythrocyte regarding vitamin B6. 
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Figure 1.5:  A hypothetical model for a potential cross talk between the parasite and 
erythrocyte regarding vitamin B6. Pyridoxal (PL), pyridoxamine (PM) and pyridoxine (PN) 
are taken up into the erythrocyte by passive diffusion. In the erythrocyte, they are 
phosphorylated by the pyridoxal kinase (PdxK) to their phosphate ester forms. The 
phosphorylated vitamers can be dephosphorylated by the alkaline phosphotase (AP) upon 
which they can exit the erythrocyte. Pyridoxamine 5-phosphate (PMP) and pyridoxine 5-
phosphate (PNP) are converted to the co enzyme form pyridoxal 5-phosphate (PLP) by the 
respective oxidase. PL, PN, and PM in the erythrocyte can be passively taken up by the 
parasite. The parasitic pyridoxal kinase converts them into their phosphorylated forms. It is 
not clear if PMP and PNP can be converted to PLP in the parasite. The respective oxidases 
have not yet been identified.  PMP, PNP and PLP can also be dephosphorylated in the 
parasite by the phosphotase. The parasite is able to synthesize pyridoxal 5-phosphate de 
novo utilizing the Pdx1/Pdx2 complex and the substrates ribose 5-phosphate (R5P), 
glyceraldehyde 3-phosphate (G3P) and glutamine. 
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1.7 Polymorphism of the human erythrocytic pyridoxal 
kinase 
 
  The human pyridoxal kinase (PdxK) is a polypeptide of 312 amino acid residues and 
is present in various human tissues such as liver, heart, kidney, skeletal muscles, 
brain, small intestine, spleen etc. It is also present in blood cells such as leukocytes 
and erythrocytes (Hanna, Turner et al. 1997). 
  Thirty years ago it was reported that the pyridoxal kinase activity in erythrocytes of 
African – Americans was strikingly lower than that of individuals with European 
ancestry. This racial difference in activity was found to be tissue specific, with 
leukocyte and fibroblast PdxK activity being the same in both racial group (Chern and 
Beutler 1975). These findings were confirmed and it was suggested that the selective 
pressure of malaria was the cause of the lowered erythrocyte PdxK activity among 
individuals of African ancestry (Martin, Miller et al. 1978) 
  The mechanism by which evolution has selectively lowered the PdxK activity in 
erythrocytes but not in the other cell types has also been elucidated. It was proposed 
that an 8 bp insertion in the promoter region of the pdxk gene leads to an increase in 
activity of the erythrocytic PdxK. It has also been demonstrated that the 8 bp insertion 
introduces a binding site for a putative core promoter binding protein (CPBP) which is 
known to increase transcriptional activity at least four-fold. Further investigations 
revealed that the putative CPBP binding site was adjacent to a binding site for an 
erythrocyte specific transcription factor, the erythroid Krüppel like factor (EKLF). 
These findings allow the hypothesis that the presence of the 8 bp insertion would 
lead to an increased transcription of pdxk in erythrocytes only and thereby leading to 
enhanced activity. It also means that the absence of the 8 bp insertion would lead to 
lower erythrocytic PdxK activity (Flanagan and Beutler 2006)
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1.8   Aim of Project 
 
The severity of malaria infection depends a great deal on host factors. Although 
factors such as natural acquired immunity play a key role in shaping the clinical 
outcome of the disease, genetic factors that have evolved due to the selective 
pressure of malaria on the human genome are known also to a play an important part 
on this aspect. Today, host genetic polymorphisms that are known to reduce the 
susceptibility to malaria provide a foundation for the investigation of host-parasite 
interactions. 
  The erythrocyte is the main spot for genetic polymorphisms that are known to offer 
protection against malaria and thus are predominant in endemic regions. 
An early study reported that the erythrocytic pyridoxal kinase activity is lowered in 
American blacks as opposed to American whites. Another study attempted to 
associate this lowered activity with reduced susceptibility to malaria. Recently, the 
genetic basis for the lowered erythrocytic PdxK activity was resolved and it was 
shown that an 8 bp deletion in the promoter region of the pdxk gene led to reduce 
activity of the enzyme in erythrocytes. Although the lowered erythrocytic PdxK activity 
has been associated with protection against malaria, its effect on the parasite has 
never been studied. 
  Therefore, the aim of this project was to test the hypothesis that the lowered 
erythrocytic pyridoxal kinase activity could be a genetic trait that offers protection 
against malaria. It was my goal to provide further evidence for this hypothesis by 
investigating the effect of the lowered erythrocytic Pdxk activity on P.falciparum in an 
in vitro culture system and to disclose the mechanism of protection of this genetic 
trait. 
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2 Materials and Methods 
 
 
2.1 Materials 
 
 
2.1.1 Chemicals 
Acetic acid           J.T. Baker, Deventer, NL 
Agarose       invitrogen Gmbh Karlsruhe, 
Acrylamide/Bis solution 30%   Biorad, Munich, DE 
Albumax II      Gibco Invitrogen, Karlsruhe, DE 
Ampicillin       Sigma Aldrich, Taufkirchen, DE 
Ammouniumpersulphate (APS)   Sigma Aldrich, Taufkirchen, DE 
BactoTM Agar      BD, Heidelberg, DE 
BactoTM       BD, Heidelberg, DE 
D-(+) glucose      Sigma Aldrich, Taufkirche, DE 
D-sorbitol       Fluka, Sigma Aldrich 
Dimethylsulfoxide (DMSO)    Sigma Aldrich, Taufkirchen, DE 
Dodecylsulfat-Na-salt (SDS)    Serva, Heidelberg, DE 
Ethylendiamintetraacetic acid (EDTA)   Acros 
Ethanol absolute 100 %     J.T. Baker, Denventer, NL 
Ethanol 96 %                      JT Baker, Deventer, NL 
Ethidiumbromide 1 % (10mg/ml)   Carl Roth GmbH, Karlsruhe 
Ethidiumbromide      Sigma Aldrich, Taufkirchen, DE 
Gentamicin 50 mg/ml     Gibco Invitrogen, Karlsruhe, DE 
Giemsa solution     Merck, Darmstadt, DE 
Glycerol       Carl Roth GmbH, Karlsruhe, DE 
HEPES (N’-2-Hydroxyethylpiperazine-      
N’-2 ethanesulphonic acid)   Carl Roth GmbH, Karlsruhe 
Human AB serum      Blood bank, Uniclinic Heidelberg 
Hydrogenchloride     Merck, Darmstadt, DE 
Hypoxanthine (10 mM)    ccpro, Oberdorla, DE 
Potassiumacetate      VWR, Darmstadt, DE 
Potassiumchloride     AppliChem GmbH, Darmstadt, DE 
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Methanol       JT. Baker, Deventer, NL 
Sodiumacetate     Grüssing, Filsum, DE 
Sodiumchloride     Riedel, Hannover, DE 
Tri-sodiumcitrate-dihydrate   Carl Roth GmbH, Karlsruhe 
Sodiumhydrogencarbonate   Grüssing, Filsum, DE 
Sodiumhydroxide     Merck, Darmstadt, DE 
Sodium-dodecylsulphate (SDS)   Applichem, DE 
Phosphate buffered saline (PBS)   Sigma Aldrich, Taufkirchen, DE 
Pyrimethamine      Sigma Aldrich, Taufkirchen, DE 
RNA DNA Stabilization reagent for blood Roche, Mannheim, DE 
and bone marrow     Roche Mannheim, DE 
RPMI1640 with L- Glutamine   Gibco, Invitrogen, Karlsruhe, DE 
RPMI 1640 Medium without glutamine  Sigma Aldrich, Taufkirchen, DE 
RPMI 1640 Medium without pyridoxine  cc pro,Oberdolar,DE  
Dodecylsulfat-sodium salt (SDS)   Serva, Heidelberg, DE 
Sybr Safe DNA gel stain 10.000 x in DMSO Invitrogen GmbH, Karlsruhe, DE 
Hydrochloride acid     Merck, Darmstadt, DE 
Saponin      Sigma Aldrich, Taufkirchen, DE 
Tris       Carl Roth GmbH, Karlsruhe, DE 
Trishydrochlorid     Carl Roth GmbH, Karlsruhe, DE 
Triton x 100      Carl Roth GmbH, Karlsruhe, DE 
Tween 20      Gerbu Biochemicals GmbH, 
Gaiberg, DE 
2.1.2 Buffers, media and solutions 
 
Buffer 
 
10 x SDS running buffer    30.3 g Tris base 
144 g   glycine 
10 g      SDS 
 fill to 1 litre with H2O 
 
10 x TBS buffer:     500 mM Tris pH 8 
1,5 M     NaCl 
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fill to 1 litre with H2O 
 
1 x TBST buffer     1 x TBS buffer 
        0.1% Tween 
 
Transfer buffer     48 mM Tris 
39 mM Glycine 
20 % Methanol 
 
2 x SDS sample buffer    2 ml 0.5M Tris HCL pH 6.8 
1.6 ml Glycerol 
1.6 ml 20 % SDS  
1.4 ml dH2O 
0.4 ml 0.05 % bromphenol blue 
7 µl β-mercaptoethanol 
 
0.4 M PHEM buffer          240 mM 1,4 Piperazinediethanesulfonic   
                                                                         Acid (Pipes) 
         100 mM  N’-2-Hydroxyethylpiperazine-      
          N’-2 ethanesulphonic acid (Hepes) 
8 mM MgCl 
40 mM EDTA  
 pH 6.9 
 
Fix 1       0.2 M PHEM Buffer 
8 % PFA 
0.2% glutaraldehyde  
 
 
Fix 2       0.1 M PHEM buffer 
4 % PFA  
0.1% glutaraldehyde 
 
Cellpack buffer                                                  Sysmex, Germany 
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0,5 M Ethylenediaminetetraacetic acid             186,1g Na2EDTA, pH  8 (with NaOH) 
 EDTA (1 L)         
 
Lysis buffer      12mM triethanolamine hydrochloride  
         NaOH, pH 7.4 
  
 
50 x TAE buffer (1 L)    2 M Tris base (242 g) 
1 M glacial acetic acid (57,1 ml) 
0,05 M EDTA, pH 8 
 
10 x TBE buffer (1 L)    890 mM Tris base (108 g) 
890 mM boric acid (55 g) 
20 mM EDTA, pH 8 
 
RIPA buffer (500 ml)    50 mM Tris  pH  8 
       150 mM NaCl 
       5 mM EDTA 
       50 mM NaF 
       0.5 % NaDOC 
       0.1 % SDS 
       1 % Triton x 100   
  
 
Medium 
 
LB medium for bacterial culture (1 L)      5 g yeast extract 
 5 g NaCl 
10 g trypton 
(15 g agar for plates) 
ampicillin 0,1 mg/ml for selection 
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Complete cell culture medium (500 ml)            RPMI1640 with L-Glutamine (Gibco) 
12 ml AB serum (heat inactivated 
56°C) 
0,1 mM hypoxanthine 
250 µl gentamicin (Stock 50mg/ml) 
2,5 g albumax (filtered sterile) 
 
 
 
RPMI basic medium (500ml)                            RPMI 1640 with L-Glutamine (Gibco)  
 
                  
Solutions 
 
Thawing solution 1      12 % NaCl 
 Filtered steril 
 
Thawing solution 2      1.6 % NaCl 
Filtered steril 
 
Thawing solution 3      0.9 % NaCl 
0.2 % Glucose 
           Filtered steril 
 
Freezing solution (50 ml)    3 % sorbitol (1,5 g) 
0.65 % NaCl (0,325 g) 
28 %  glycerol (14 ml) 
Filtered 
 
Commassie solution    20 %     Methanol 
72.5 %   H2O 
7.5 %    Acetic acid 
0.04 g   Commassie 
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Destain solution     20 %     Methanol 
72.5 %   H2O 
7.5 %    Acetic acid 
 
 
Ringer solution (1 L)    122.5 mM NaCl 
        5.4 mM KCl 
        1.2 mM CaCl2 x 2H2O 
        0.8 mM MgCl2 x 6H2O 
        10 mM Hepes 
        11 mM D-Glucose 
        1 mM NaH2PO4.H2O 
        p.H 7.4 
 
 
2.1.3 Kits 
Fast Sybr Master Mix    Applied bioystems (ABI),DE 
mRNA Isolation Kit for blood 
and bone       Roche, Mannheim, DE 
QIAamp DNA Blood Kit    QIAGEN, Hilden, DE 
QIAgen PCR Purification Kit    QIAGEN, Hilden, DE 
QIAquick Gel extraction Kit    QIAGEN, Hilden, DE 
RETROscript     Ambion, Huntingdon, UK 
RNeasy Mini Kit      QIAGEN, Hilden, DE 
RNase-Free DNase Set    QIAGEN, Hilden, DE 
Turbo DNA free Kit      Ambion, Huntingdon, UK 
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2.1.4 Equipments 
 
Adventurer ProTM balance   Ohaus 
Computer hardware    iMac 
Computer software 
7500 system software   Applied biosystems 
Bioedit    Ibis Therapeutics, Carlsbad 
Endnote    Thomson Reuters 
EnzymeX3.1    Mekentosj.cin 
FACS DIVA    BD, DE 
ImageJ      NIH, USA 
Microsoft office 2008  Microsoft, 
Quantity one®   BIO-RAD 
Primer Express    Applied biosystems 
Prism 5 GrahpPad Software 
 
Centrifuge 
Microcentrifuge GALAXY mini vWR 
Biofuge pico    Heraeus, Kendro, Langensolbold, DE 
Fresco 21     Heraeus Instruments, Hanau, DE 
Megafuge 1.0 R    Heraeus Instruments, Hanau, DE 
 
Vi-CellTM XR Cell Viability Analyzer   Beckman Coulter, Krefeld, DE 
 
DNA Workstation (DNA/RNA UV cleaner) G. Kisker, Steinfurt, DE 
Eclipse E 200 Microscope    Nikon 
Electrophoresis System    BIO-RAD, Munich, DE 
 
Freezer 
-80°C     Heraeus GmbH, Hanau, DE 
Premium no frost (-20°C)  Liebherr, Biberach, DE 
Premium (4°C)   Liebherr, Biberach, DE 
 
Flow cytometer BD LSR II                       Becton Dickenson, DE 
Geldoc XR       Biorad, Munich, DE 
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Herasafe bench     Heraeus GmbH, Hanau, DE 
Incubator Heracell 150    Heraeus / Thermo, Hanau, DE 
Isotherm System 3880    Eppendorf, Hamburg, DE 
Microwave LG.      
Mini PROTEAN 3     BIO-RAD, Munich, DE 
Mini Sub cell      BIO-RAD, Munich, DE 
Multipipette, 10 µl, 100 µl, 300 µl             Eppendorf, Hamburg, DE 
Mastercycler epgradient    Eppendorf, Hamburg, DE 
Mini-PROTEAN® 3 CELL    BIO-RAD, Munich, DE 
Nanodrop      Peqlab, Erlangen, DE 
Ph Meter       Schott, DE 
Pipette controller accu jet pro   Brand GmbH, Wertheim, DE 
Pipette controller accu jet pro    Brand GmbH, Wertheim, DE 
Pipettes, 0,1-2,5 µl, 2-20 µl, 
20 µl-200 µl, 100 µl-1000 µl   Eppendorf, Hamburg, DE 
PowerPacTM Basic Power Supply  BIO-RAD, Munich, DE 
PowerPacTM HC Power Supply   BIO-RAD, Munich, DE 
Printer hpdeskjet 6122    Hewlett Packard, Heidelberg, DE 
7500 Real time PCR system    Applied biosystems, Foster City, USA 
Databases: 
PlasmoDB    www.plasmobd.org 
NCBI      www.ncbi.nlm.nih.gov/pubmed/ 
GeneDB    www.genedb.org
 
2.1.5 Consumables 
 
ABgene PCR plates    Thermo Scientific, Waltham,USA 
Amersham HyperfilmTM ECL   GE Healthcare, Buckinghamshire, DE 
Cryotobes      Nunc, Langenselbold, DE 
Cover for 96 well plate    Greiner Bio-one, Firckenhausen, DE 
FIA-Plate, black 96 well plate   Greiner Bio-one, Frickenhausen, DE 
Filter Tip 10E, 20, 100, 200, 1000  Greiner Bio-one, Frickenhausen, DE 
Filter cap cell culture flask, 25cm2, 175cm2 Greiner Bio-one, Firckenhausen, DE 
Kodak BioMax MR film    Sigma Aldrich, Taufkirchen, DE 
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Universal Tips, yellow, blue   Greiner bio-one, Firckenhausen, DE 
PP test tube, 15 ml, 50 ml    Greiner bio-one, Firckenhausen, DE 
Pipette, 1 ml, 2 ml, 5 ml, 10 ml, 25 ml  Greiner bio-one, Firckenhausen, DE 
Safe lock tubes 1,5 ml    Eppendorf, Hamburg, DE 
RNase free Biopure 1,5 ml   Eppendorf, Hamburg, DE 
PCR softstrips 0,2 ml, colour   Biozym Scientific GmbH 
Oldendorf, DE 
 
epT.I.P.S. Reloads 2-200 µl   Eppendorf, Hamburg, DE 
epT.I.P.S. Reloads 20-300 µl    Eppendorf, Hamburg, DE 
96 well plate (black and clear)   Greiner Bio-one, Firckenhausen, DE 
Ultrafree-MC Centrifugal filter device  Millipore, DE 
Millipore Centrifugal filter units   Millipore, DE 
Immobilon Millipore transfer membranes Millipore, DE 
PVDF Filtertype 
 
2.1.6 Enzymes, Antibodies and Ladders 
 
Enzymes 
 
All restriction enzymes and corresponding buffers were purchased from New 
England Biolabs. 
 
DNase was purchased from Ambion, Huntingdon, UK, Taq poylermase from 
Fermentas, St Leon Rot, DE. 
 
 
DNA Ladder 
GenerulerTM 1 kb DNA Lader    Fermentas, St Leon-Rot, DE 
100 bp DNA Ladder        Invitrogen, Karlsruhe, DE 
DNA Molecular Weight Marker III 
(Digoxigenin-labeled)     Roche, Mannheim, DE 
 
Antibodies 
Anti human pyridoxal kinase                              Santa Cruz, Heidelberg,  DE 
Secondary antibody goat anti rabbit                   Dianova, Hamburg, DE 
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2.1.7 P. falciparum laboratory strains 
 
Table 2.1.1 lists the P. falciparum laboratory strains that were used in this work 
 
P. falciparum strain Country of origin Donated from 
Dd2 Indochina Prof. Lanzer 
HB3 Honduras Prof. Lanzer 
3D7  Prof. Lanzer 
FCR3 The Gambia Prof. Lanzer 
 
 
 
 
 
2.1.8 Oligonucleotides 
 
Primer Forward primer Reverse primer Accession 
number 
pdxk  5' TAATAACTCGAGGGCCCTGCA 
GGCACTTGA GAG 3' 
5' TAATAAGGATCCGCG 
GATGACGTGGCTCTGTATG 3' 
NCBI AP001752 
+ 
insertion 
5'GGCCACCTGGCGCGGCG3' 5'TGCCGGGCCTGGCCGCG3' NCBI AP001752 
- 
insertion 
5'GGCCACCTGGCGCGGCC3' 5'TGCCGGGCCTGGCCGCG3' NCBI AP001752 
pdxk 80 
bp 
5'CCCAGCGTTTCGGGCGGC3' 5'GCTGGGAGGAAGCGAAACC
G3' 
NCBI AP001752 
pfpdx1 5'TACTCCAGCTGATGCAGCCAT3' 5'AAAACTCCATCCATTCCTAA
TTGC3' 
PlasmoDB 
PFF0775w 
pfpdxk 5'TATGTGATCCCGTTATGGGAGA
T3' 
5'CACGTTCATCAACATATAGT
CTTCCG3' 
PlasmoDB 
PF14_0570 
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2.2 Methods 
 
2.2.1 Screening human genomic DNA for the 8 bp insertion in the                        
promoter region of the pyridoxal kinase gene 
 
A PCR based method was developed for screening human genomic DNA of various 
individuals for the 8 bp insertion. The sequence for the human pyrdoxal kinase gene 
was obtained from the NCBI data base. 
 
2.2.1.1 Isolation of human genomic DNA  
 
9 ml venous blood from individuals was collected into EDTA tubes. The blood was 
transferred to a 15 ml falcon tube and centrifuged at 4000 rpm for 10 min at 25°C. 
After centrifugation, the plasma fraction was discarded. The fraction with the white 
blood cells (buffy coat) was carefully collected with a pipette and transferred into a 
fresh 15 ml falcon tube. The buffy coat was washed twice with 2 ml PBS and each 
time carefully transferred into a fresh 15 ml falcon tube. 200 µl of the buffy coat was 
used for the isolation of gDNA.  
gDNA was isolated using the QIAamp DNA  blood kit  following the kit instructions, 
eluted in 80 µl elution buffer and stored at 4°C. The DNA concentration of each 
sample was determined using the Nanodrop. 
 
Figure 2.2.1: Schematic drawing of the different blood fractions.  The drawing shows the 
3 main fractions obtained after blood is centrifuged at 4000 rpm for 10 min. The red fraction 
shows the erythrocytes, the thin white fraction the leukocytes (buffy coat) and the upper 
yellow fraction is the plasma. 
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2.2.1.2 Whole genome amplification (Genomiphi) 
 
Whole genome amplification (Genomiphi, GE Healthcare, UK) was used to amplify 
gDNA samples from kilifi Kenya to increase the amount of DNA.  35 gDNA samples 
from Kilifi were amplified using the following procedure: 
1 µl of template DNA was added to an eppendorf tube and mixed with 9 µl of sample 
buffer. The mix was heated for 3 min at 95°C and then cooled to 4°C on ice. 9 µl of 
reaction buffer was mixed with 1 µl of enzyme mix and then added to the cooled 
sample. The samples were incubated at 30°C for 2 h and then heat inactivated by 
incubating for 10 min at 65°C. Samples were then cooled to 4°C on ice. 
 
 
2.2.1.2.1 Purification of genomiphi amplified samples
 The whole genome amplified samples were purified prior to PCR reactions. 20 µl of 
water was added to each sample. 4 µl of sodium acetate /EDTA buffer was added to 
the samples and mixed. 100 µl of 100 % ethanol was added to each sample to a 
concentration of 70 % ethanol and kept at 4°C overnight. The next day the samples 
were centrifuged for 15 min at 12000 rpm. The supernatant was discarded and the 
DNA pellet was washed with 70 % ethanol by centrifugation for 1 min at 12000 rpm. 
The supernatant was discarded and the pellets were air dried for 2-5 min. The pellet 
was resuspended in an appropriate amount of TE or water. 
 
2.2.1.3 Polymerase Chain Reaction (PCR)  
 
PCR was used to amplify fragments at the region of interest in the promoter of the 
pdxk gene using gDNA from different individuals as template. The platinum Pfx 
polymerase which possesses a 3’ to 5’ proof reading function was used for the 
amplification of a 700 bp fragment.  
The PCR reaction was optimized by testing different annealing temperatures and 
varying the Magnesium concentration.  Since the region of interest is very GC rich, 
PCR enhancer solution was added to the reaction mix.  
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A standard reaction mix was prepared composed of: 
3 µl      gDNA 
5 µl     10 x PCR buffer 
5 µl      Enhancer 
5 µl      2 mM dNTPs mix 
1 µl      50 mM MgSO4  
0,5 µl   5’ Primer (25 pmol) 
0,5 µl   3’ Primer  (25 pmol) 
0,5 µl   Pfx DNA polymerase 
H2O to a total volumen of 50 µl 
The annealing temperatures (AT) of the Primers were approximated: 
Tm ≈ 4(Cn + Gn) + 2 (An + Tn)                          AT≈ Tm – 5 
Tm is the melting temperature and n the number of nucleotides in the annealing part 
of the primer. For the reaction, the AT of the Primer with the lower AT was used. The 
5’ primer possesses a XhoI restriction site and the 3’ primer a BamHI site.  The PCR 
was run under standard conditions: 
 
 
 
 
 
94°C             6 min 
94°C             45 s 
56.7°C          30 s       
72°C             1 min 
72°C              4 min 
4°C                 ∞             
35 x 
 
 
2.2.1.4 Agarose gel electrophoresis 
The PCR fragments were separated on different percentages of agarose ranging 
from 0.8 to 1.5 % depending on the size of the fragment. The appropriate quantity of 
agarose was added to 1 x TAE buffer and the mixture was boiled in a microwave until 
the agarose was completely dissolved. Ethidium bromide was added to a final 
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concentration of 1 µg/ml. Ethidium bromide intercalates in DNA allowing visualisation 
of DNA by UV irradiation. 10 µl of the PCR sample was mixed with loading buffer 
(1:5, v/v) and loaded on the gel. As a size marker the 1 Kbp ladder (Fermentas) was 
used. Electrophoresis was performed at a constant voltage of 120 V in TAE.  The 
result was photographed and documented with the BIO-RAD Gel DOCTM XR imaging 
system. 
 
2.2.1.5 PCR purification 
 
After a successful PCR reaction, the remaining PCR product was purified using the 
QIAgen PCR Purification kit following the kit instructions. The system is based on 
DNA absorbing to a silica membrane in the presence of a high salt concentration 
while contaminants pass through the column. Impurities are efficiently washed away 
and the pure DNA is eluted with 30 µl of water. 
 
 
 
 
 
 
2.2.1.6 Cloning of the 700bp PCR fragment 
 
2.2.1.6.1 Competent cells 
XL1 blue cells were made competent under sterile conditions by a method according 
to Hanahan (Hanahan, 1983). The method is based on the permeabilisation of the 
cell membranes. A 5 ml pre-culture (in LB medium) of non competent XL1 blue cells 
was grown in a shaker at 37°C overnight. The next day 50 ml of LB and 2 ml of pre-
culture was incubated again in a shaker at 37°C till an OD of 0.3-0.4 was reached 
(optical density at 600 nm measured in an eppendorf photometer). The culture was 
transferred into a 50 ml falcon and centrifuged at 2400 rpm for 10 min at 4°C. The 
supernatant was discarded and the tube was placed upside down on paper for one 
minute to dry.  The cell pellet was re-suspended in 15 ml cold TBF1 buffer and 
incubated on ice for 60 min. The solution is centrifuged at 2400 rpm for 10 min at 
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4°C. The supernatant was again discarded and the cell pellet was resuspended in 
900 µl TBF2 buffer. Aliquots of 100 µl cell suspension were made on ice and frozen 
away at -80°C. 
 
 
2.2.1.6.2 Restriction analysis and digestion 
The PCR fragments and the pBluescript plasmid were digested for subsequent 
cloning. A standard reaction mix was prepared with the following content: 
30 µl DNA 
2 µl XhoI 
2 µl BamHI 
4 µl reaction buffer 2  
2 µl H2O 
Total volumen 40 µl 
The reaction is incubated for 2 h at 37°C. 
 
2.2.1.6.2.1   Dephosphorylation of the plasmid 
For the ligation of two DNA ends, at least one 5´ end must still have its phosphate 
group.  The phosphate groups can be removed by an alkaline phophatase to prevent 
religation of the plasmid vector. 1 µl of the calf intestinal alkaline phosphotase (CIP) 
was therefore added to the reaction mix with the vector 30 min prior to end of 
incubation. 
 
2.2.1.6.3 DNA extraction from agarose gel 
After restriction the reaction mix was loaded on a 1% agarose gel.  To increase the 
purity of the DNA to be cloned, the PCR and plasmid fragment were cut out of the gel 
and extracted from agarose gel with the QIAquick Gel Extraction Kit (Qiagen). The 
protocol using a micro centrifuge included in the Kit was followed. The System is 
based on that DNA absorbing to a silica membrane in the presence of high salt while 
contaminants or impurities pass through. 
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2.2.1.6.4 Ligation 
For the ligation of the digested DNA fragment and plasmid, a standard reaction mix 
with the following component was prepared: 
 
1 µl plasmid 
8 µl PCR fragment 
1 µl ligation buffer (10x) 
The mix was incubated for 3 hours at room temperature. 
 
2.2.1.6.5 Transformation of XL1 blue competent cells 
100 µl of the competent cells were used for the transformation of the total ligation 
mix. The competent cells were removed from the -80°C freezer and thawed on iced. 
The cells were then added to the tube with the ligation mix, incubated on ice for 20 
min, heat shocked for 40 seconds at 42°C and immediately transferred to ice. 1 ml 
LB media was added and the cells were incubated horizontally in a shaker (37°C, 
240 rpm) for 1 hour. The mixture was then evenly spread on LBamp plate and 
incubated overnight at 37°C.  
 
 
 
2.2.1.6.6  Plasmid preparation from bacteria 
Small – to large- scale preparations based on alkaline lysis of bacteria cells were 
performed to isolate plasmids from bacteria. 
 
 
2.2.1.6.7 Small scale preparation (Miniprep) 
Individual bacteria colonies from LBamp plates were selected to inoculate 1 ml LBamp 
medium in culture test tubes. The cultures were incubated overnight at 37°C in a 
shaker (240 rpm). The following day the cultures were transferred to eppendorf tubes 
and centrifuged at 13000 rpm. Plasmids were then isolated from the cell pellet using 
the commercially available QIAprep Spin Plasmid Miniprep Kit following the kit 
instructions. 
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2.2.1.6.8 Large scale preparation (Maxiprep) 
Plasmid large-scale preparation was carried out using the commercially available 
high Pure plasmid maxi kit by following the kit instructions. 50 ml culture was used. 
 
 
 
 
2.2.1.6.9 Restriction analysis of isolated plasmids 
To determine if the cloning was successful, 2 µl of the plasmid was digested in the 
following reaction:  
2 µl plasmid 
1 µl BamHI 
1 µl XhoI 
2 µl reaction buffer 2 
14 µl H20 
The reaction mix was incubated for 2 h at 37°C. 
 
After incubation the reaction mix was loaded on a 1 % agarose gel and all plasmids 
with the 700 bp fragments were considered positive clones. 
 
 
 
2.2.1.7  Nested PCR for screening the 700 bp PCR fragments for the      
 presence of the 8 bp insertion 
 
2.2.1.7.1 Screening clones for the presence or absence of the 8 bp insertion  
Positive clones were screened for the presence or absence of the 8 bp insertion in 
the 700 bp fragment using PCR with allele specific primers. Each clone was 
screened in two parallel PCR reactions using allele specific 5´ primers with the 8 bp 
insertion or without the 8 bp insertion and the fermentas Taq polymerase.  
The reaction mix for the nested PCR with allele specific 5´primers consisted of the 
following components: 
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1 – 2 µl plasmid/PCR product 
5 µl 10x PCR buffer 
5 µl Enhancer 
5 µl dNTPs mix (2 mM) 
1 µl MgSO4 (50 mM) 
0.5 µl 5´primer +insert/-insert (25 pmol) 
0.5 µl 3´primer (25 pmol) 
0.5 µl fermentas taq polymerase 
H2O to a total volume of 50 µl.
 
 
The PCR was run under standard conditions with the following programm: 
 
94°C             6 min 
94°C             45 s 
59°C             30 s         
72°C             1 min 
72°C              4 min 
4°C                 ∞             
30 x 
 
One positive clone with the 8 bp insertion and one without the 8 bp insertion were 
sent for sequencing. 
 
 
2.2.1.7.2 DNA sequencing 
DNA sequencing was done by GATC (Konstanz, Germany), using the Sanger 
dideoxynucleotide method (Sanger et al., 1977). PCR fragments were purified, 
solved in water and sent with the respective oligonucleotide.  
The following concentrations and volumes were sent in for sequencing: 
 
 PCR Product:    10-50 ng/µl in 30 µl 
 Plasmid:             30-100 ng/µl in 30 µl 
Oligonucleotide:  10 pmol/µl in 30 µl 
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The sequences were analysed with the BioEdit software. 
 
 
2.2.1.7.3 Work flow for the established PCR screen 
A 700 bp PCR fragment was amplified from gDNA samples from different individuals. 
The PCR fragment was then used as a template in a nested PCR. The control clon 
for the insertion (C+) and the control clone without the insertion (C–) were always 
used as a control for each nested PCR. Two parallel reactions were carried out for 
each template with an allele specific forward primer for the insertion or without the 
insertion in each reaction respectively. 
42 Caucasians from Heidelberg and 33 Africans from Kilifi Kenya were screened for 
the 8 bp insertion in the promoter region of the pyridoxal kinase gene. Individuals that 
were homozygous for the insertion event, were referred to as bearing the insertion 
genotype (+/+), heterozygous genotype (+/-) and individuals without the insertion 
event as bearing the deletion genotype (-/-) 
 
                                                                                        
Figure 2.2.2: Schematic drawing of the PCR based method for screening human gDNA 
for the 8bp insertion. The drawing shows the PCR set up used for screening for the 8bp 
insertion. The Light orange bars          represent the 8 bp insertion allele and the dark orange 
bars          represent allele without the insertion. -/- stands for individuals homozygous for the 
8 bp deletion event, +/- for heterozygote and +/+ for individual homozygous for the 8 bp 
insertion event. 
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2.2.1.8 Alternative PCR Screen 
 
A small fragment of 80 bp around the region of interest in the promoter area of the 
hpdxk gene was amplified. The 700 bp PCR fragment amplified from the genomic 
DNA from various individuals was used as template and the control clons for the 
insertion (C+) and deletion (C-) were used as controls for the PCR.  A PCR reaction 
mix with the following components was prepared: 
3 µl gDNA 
5 µl 10x reaction buffer (10 x) 
5 µl  Enhancer 
5 µl  dNTPs (2mM) 
1 µl  MgSO4 (50mM) 
0.5 µl forward primer (25 pmol) 
0.5 µl reverse primer  (25 pmol) 
0.5 µl Pfx Taq polymerase 
H2O to a total volume of 50µl. 
 
The PCR was run with the following program: 
 
94°C 6 min 
94°C 45sec 
58°C 30sec 
72°C 30sec 
72°C 4 min 
4°C ∞ 
35 x 
 
2.2.1.8.1 Metaphor gel electrophoresis 
The difference in size of fragments with and without the 8 bp was analysed on a 
metaphor gel. A 4% metaphor gel was prepared by adding 4 g of metaphor to 100 ml 
of TAE buffer. The suspension was stirred for 20 min and then heated gently in a 
microwave until the gel was completely dissolved. 
The gel was run at 80 V for 1 h. The result was photographed and documented with 
the BIO-RAD Gel DOCTM XR imaging system. 
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Figure 2.2.3: Schematic drawing for the 80/88 bp fragment PCR 
 
 
 
2.2.2 Cell Culture 
 
 
2.2.2.1 In vitro culture of P. falciparum 
 
P. falciparum parasites of the strain 3D7, FCR3, Dd2 and HB3 were cultured by an 
adaptation of the method of Trager and Jensen (Trager and Jensen 1976). The 
erythrocytic forms of P. falciparum were cultured in T 25 or T 75 cell culture flasks 
with RPMI1640 medium supplemented with 200 mM hypoxanthine, 20 µg/ml 
Gentamicin , 10 % A+ serum and albumax at a hematocrit of approxiamately 5 %. 
The parasitemia was checked and the medium changed every two or three days. At a 
parasitemia of 5-10 % the culture was diluted in a new culture flask to avoid death of 
parasites due to high levels of degraded toxic products in the medium. The parasite 
cultures were incubated in an atmosphere of 5 % CO2, 5 % O2 and 90 % of N2 at 
37°C. 
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2.2.2.2 Preparation of human serum and erythrocytes 
 
Human group A+ or O+ erythrocytes concentrate and A+ human serum was obtained 
from the blood bank of the German Red Cross. The human serum was prepared as 
follows. It was incubated at 60°C in a water bath for 30 min to inactivate the serum 
and then aliquoted into 10 ml falcon tubes. The tubes were then centrifuged at 4000 
rpm for 1 hour to pellet the fibrin. Thereafter the serum was kept at -20°C.  
The erythrocyte concentrate was aliquoted into 50 ml Falcon tubes and stored at 
4°C. 
 
2.2.2.3 Staining of P. falciparum with giemsa 
 
To enable determination of parasitaemia and parasite developmental stage, thin 
smears of the culture were made as follows: 50 µl of culture was spread evenlyonto 
the surface of a clean microscope slide, air dried, fixed in 100 % methanolfor 1 min, 
and air dried. Fixed cells were stained for 10-20 min in a solution of 10 % Giemsa, 
washed with water and allowed to dry. Slides were examinedmicroscopically on a 
light microscope using a 100 X objective under oilimmersion. 
 
2.2.2.4 Determining parasitemia 
 
The parasitemia is the percentage of P. falciparum infected erythrocytes. A single 
layer of stained cells was used.  Infected and uninfected erythrocytes were counted 
to a total number of 1000. The parasitemia was then calculated according to the 
following formula: (Number of infected erythrocytes/number of uninfected 
erythrocytes) x 100 = parasitemia in % 
  
2.2.2.5 Freezing  parasites   
     
Only the parasites from the ring stage can be recovered after freezing. To guarantee 
that the parasites will appear quickly after thawing the parasitemia should be higher 
than 5 %. Infected erythrocytes were pelleted at 2000 rpm for 3 min. The supernatant 
was then removed, and the sediment re-suspended in 1 volume of sterile freezing 
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solution (28 % Glycerol, 3 % Sorbitol, and 0.65 % NaCl). The suspension was gently 
mixed, filled into a cryotube and snap frozen in an ethanol/dry ice slurry for 15 min. 
The tube was then transferred to –80°Cfor not less than one day, before being stored 
at –196°C in liquid nitrogen. 
 
2.2.2.6 Thawing parasites      
 
The cryotube was removed from the liquid nitrogen tank and thawed at 37°C in a 
water bath for 2 min before being transferred to a 15 ml falcon tube. Per 1 ml of blood 
200 µl of thawing solution 1 was added at a rate of 2 drops per second with constant 
mixing. After a 5 min incubation period at RT, a further 9 ml of thawing solution 2 was 
then gently added drop wise and the suspension was centrifuged at 2000 rpm for 3 
min. The supernatant was discarded. 7 ml of thawing solution 3 was added drop wise 
and the suspension was again centrifuged at 2000 rpm for 3 min. The supernatant 
was removed and the parasite pellet washed in 3ml ofcomplete RPMI medium, 
resuspended in 1 ml of complete RPMI medium and transferred to a T25 flask 
containing fresh 10 ml RPMI medium. 0.5 ml of fresh erythrocytes was then added 
and the flask transferred to the incubator. All solutions were pre-warmed to 37°C 
before starting the thawing procedure. 
2.2.2.7 Parasite synchronisation with sorbitol   
 
Sorbitol treatment causes osmotic lysis of late stage trophozoites (Lambros and 
Vanderberg 1979). This selective lysis by osmotic shock is possible due to the 
presence of an induced transport pathway in the red cell membrane that is 
permeable to sorbitol, and absent in ring stage parasites. The parasite culture was 
transferred to a 15 ml falcon tube for a T25 flask culture or to a 50 ml falcon tube for 
a T75 culture. The parasite culture was centrifuged at 2000 rpm for 3 min and Culture 
media was removed. The parasite pellet was resuspended in 9 ml ( or 30 ml for a 
T75 culture) of sterile, pre-warmed 5% D-sorbitol solution and incubated for 5 min at 
37°C in a water bath. The suspension was then centrifuged (2000 rpm, 3min, RT), 
the pellet was washed once in 3 ml culture medium, resupended in 1 ml medium and 
transferred to a new flask with 10 ml fresh medium. For a tightly synchronised 
culture, this procedure was repeated in the next cycle at the transition from schizonts 
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to ring stage, were only the first few rings survived with an internal age difference of 
only a few hours. 
2.2.2.8 Gelatine flotation 
 
There are different methods for the enrichment of trophozoite and schizont stages. 
One of them used in this study,is the enrichment by gelatine flotation which is based 
on different sedimentation rates depending on the presence of knobs on the surface 
of the infected erythrocytes (Jensen 1978). The parasite culture is centrifuged at 
2000 rpm for 3 min at RT, the medium is discarded and pellet resuspended in 4.5 ml 
(T25 flask) or in 9 ml (T75 flask) of preheated 0.5 % sterile gelatine in RPMI. 
Parasites are incubated at 37°C for 1 hour, and the supernatant is transferred to a 
new falcon tube, centrifuged at 2000 rpm for 3 min, washed once in medium or 
binding buffer (if followed by panning or adhesion assay) and finally resuspended in 
the amount of medium or binding buffer wanted, usually 10 ml. 
 
 
 
 
 
2.2.3 Growth experiments 
 
2.2.3 1 Blood collection and preparation of erythrocytes 
 
21 ml venous blood was collected from individuals who were homozygous for the 8 
bp insertion (+/+), heterozygous (+/-) and homozygous for the deletion event (-/-). 
The blood was collected into Li-heparin tubes. The blood was transferred into 50 ml 
falcon tubes and centrifuged at 4000 rpm for 10 min. The plasma fraction and buffy 
coat were discarded. The erythrocytes were washed 2-3 times with RPMI 1640 basic 
medium and each time the buffy coat was carefully removed. The erythrocytes were 
stored as 50 % packed cells in pyridoxine depleted RPMI 1640 medium at 4°C for 1 
week.  
Blood was collected from blood donors on a weekly basis.  
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2.2.3.2 ABO blood group test 
 
The blood group of all blood donors was determined with anti-A, anti-B and anti- AB 
monoclonal test reagents (SD-nostik Diagnostik, Germany). The human ABO blood 
group system is defined by the presence or absence of antigens A and B on the 
erythrocytes. The test reagents are used to identify the AB antigens on the red cells. 
The specific monoclonal antibodies of the test reagents agglutinate red cells 
possessing the relevant antigen or antigens. The non-occurrence of agglutination 
indicates the absence of the relevant antigen. 
One drop of test reagent anti-A, anti-B and anti-AB was placed on a clean glass slide. 
To each drop of test reagent, 1 drop of blood is added and carefully mixed. After 5 
minutes of incubation agglutination can be read. 
 
2.2.3.3 Haemoglobin variant test  
Blood donors for the growth experiments were also tested for the haemoglobin 
variants HbC, HbS and HbF. 9 ml of venous blood was collected into EDTA tube and 
sent to the central lab of the University Hospital Heidelberg for analysis. 
 
 
2.2.3.4 Growth experiment set up 
 
One week before the growth experiment a P. falciparum culture was tightly 
synchronized by treating the culture 2 times with sorbitol. Infected erythrocytes were 
added to uninfected erythrocytes from individuals bearing the +/+, +/- and -/- 
genotype to give an initial parasitemia of ca. 0,1 %. The experiment was started with 
ring stages and the culture was set up in 6 well plates with triplicates for each 
genotype. The parasites were cultivated with RPMI 1640 complete medium and 
medium depleted of pyridoxine for a period of 15-20 days. Medium was changed 
every second day and the culture was splitted at a parasitemia of 3-6 %. Parasitemia 
was determined by Giemsa stained slides and flow cytometry. 
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+/+ +/+ +/+ +/- +/- +/- - /- - /- - /- 
Figure 2.2.4: Schematic drawing showing the set up of the growth experiments. The 
drawing shows the set up for the in vitro growth experiments. The parasites were grown in 6 
well plates with 3 wells of each plate containing cultures with erythrocytes of the same 
genotype. Pyridoxine containing and pyridoxine depleted medium was used for culure. 
  
 
2.2.3.5 Flow cytometry 
Flow cytometry is a laser based technology that is used to measure characteristics of 
biological particles. The underlying principle of flow cytometry is that light is scattered 
and fluorescence is emitted as light from the excitation source strikes the moving 
particle. Flow cytometry allows qualitative and quantitative examination of whole cells 
and cellular constituents that have been labelled with a range of commercially 
available reagents such as dyes and monoclonal antibodies. Cells or particles are 
prepared as single-cell suspensions for flow cytometric analysis. This allows them to 
flow single in a liquid stream past a laser beam. As the laser beam strikes the 
individual cells, two types of physical phenomena occur that yield information about 
the cells. First, light scattering occurs that is directly related to structural and 
morphological cell features. Second, fluorescence occurs if the cells are labelled with 
a fluorescent probe. The fluorescent probes are typically monoclonal antibodies that 
have been conjugated to fluorochromes or fluorescent stains or reagents that are not 
conjugated to antibodies. There are two distinct types of flow cytometers that can be 
used to acquire data from particles. One type can perform acquisition of light 
scattering and fluorescence only. The other type is capable of acquiring scattering 
and fluorescence data but also has the ability to sort particles. Thus cytometers that 
perform acquisition without sorting are the more common of the two types. 
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2.2.3.5.1 Principles of flow cytometry instrumentation 
Flow cytometers can be described as a four interrelated system. There is a fluidic 
system that transports particles from a sample through the instrumentation for 
analysis. The primary component of this system is a flow chamber. Typically a diluent 
such as phosphate buffered saline or FACS flow (BD, Germany) is directed by air 
pressure into the flow chamber. This fluid is referred to as sheath fluid. The sample 
under analysis in the form of a single particle suspension is directed into the sheath 
fluid stream prior to sample interrogation. The pressure of the sheath flow against the 
suspended particles aligns the particles in a single-file fashion. 
The second system is an illumination system that is used for particle interrogation. 
This consists of a laser beam that intercepts a cell or particle that has been hydro 
dynamically focused by the fluidic system. Light and fluorescence are generated 
when the focused laser beam strikes a particle within the sample stream. These light 
signals are then quantified by the optical and electronic system to yield data.  
The third system is an optical and electronic system for the direction, collection and 
translation of scattered and fluorescent light signals that result when the particles are 
illuminated. The optical and electronic system of a typical flow chamber is 
responsible for collecting and quantifying at least five types of parameters from the 
scattered light and emitted fluorescence. Two of these parameters are light scattering 
properties. Light that is scattered in the forward direction (FSC) is analysed as one 
parameter. Forward scattered light is a result of diffraction. It provides basic 
morphological information such as relative cell size. Light that is scattered at 90° to 
the incident beam is refracted and reflected light – side angle light scatter (SSC). This 
parameter is an indicator of granularity within the cytoplasm of cells as well as 
surface/membrane irregularities. Fluorescence emission is detected simultaneously 
along with FSC and SSC data. Fluorescence is detected using networks of mirrors, 
optics, and beam splitters that direct the emitted fluorescence light toward highly 
specific filters. The filters collect light within the range of wavelength associated with 
each of the three fluorescent channels (FL1, FL2 and FL3). 
The fourth system in flow cytometry instrumentation is data storage and computer 
control system that interprets translated light and electrical signals and collates them 
into meaningful data for storage and subsequent analysis. 
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Figure 2.2.5: Diagram showing the instrumentation and principles of a flow cytometer 
with cell sorting 
 
 
 
2.2.3.6 Determining parasitemia with flow cytometry 
Parasitemia was determined daily or every second day during the growth experiment 
by flow cytometry.  The cultures were resuspended by shaking the flask thoroughly 
per hand. 10 µl from each culture was added to a FACS tube containing 1 ml of 
ringer solution with ethidium bromide (1 µg/µl). The suspension was mixed and 
incubated for 1-1.5 hours in the dark. The samples were analysed on a BD LSR II 
system and the parameters FSC and SSC were collected. Fluorescence was 
collected in the FL 2 channel. 
 
2.2.3.7 Short term growth experiments 
P. falciparum strains 3D7, FCR3, Dd2 and HB3 were cultivated in erythrocytes from 
individuals bearing the +/+, +/- and -/- genotypes for at least 3 weeks before the short 
term growth experiment. The cultures were cultivated in T25 flasks with pyridoxine 
containing RPMI medium. The cultures were then synchronised by treating two times 
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with sorbitol. Infected erythrocytes with ring stages were then added to fresh 
erythrocytes with the respective genotypes to an initial parasitemia of 0.1 %. The 
cultures were incubated at 37°C for 3 days and parasitemia was determined daily 
using flow cytometry.  
    
 
 
2.2.4  Erythrocyte deformability assay    
 
The deformability of erythrocytes was assessed according to the methods of Beder et 
al., 2003. The deformability of erythrocytes was determined by means of filtration 
combined with centrifugation. Diluted erythrocytes suspensions were filtered by 
centrifugation through membrane filters with pores of 5 µm in diameter. 
 
2.2.4.1 Preparation of erythrocytes   
7 ml venous blood was collected from an individual homozygous for the insertion 
genotype +/+ and from an individual homozygous for the deletion genotype -/- into 
heparin tubes and then transferred to 15 ml falcon tubes. The tubes were then 
centrifuged at 4000 rpm for 10 min at room temperature. The plasma fraction and 
buffy coat was discarded and the erythrocytes were washed twice with ringer 
solution. 
 
2.2.4.2 Erythrocyte count 
Erythrocytes were counted with the Neubauer improved cell chamber. The Neubauer 
improved cell chamber consists of 3 x 3 big squares. The central big square is 
divided into 5 x 5 small groups of squares.  The erythrocytes were diluted 1:2500 with 
cell pack buffer and 7 µl of the suspension was pippetted onto the cell chamber for 
counting. All cells on the central square were counted; cells on the boardering lines 
were not counted.  
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Figure 2.2.6: Neubauer cell chamber. The chamber consists of 3 x 3 big squares. The 
central big square consists of 5 x 5 smaller square groups. The cells on the central big 
squares were counted with the exception of cells on boarding lines. 
 
 
 
2.2.4.3 Erythrocyte filtration  
Erythrocytes were diluted 1:250 with cell pack buffer. 30 µl of the cell suspension was 
added to a Millipore centrifugal unit onto a membrane with pores of 5 µM in diameter. 
The centrifugal unit was centrifuged at 1400 rpm for 5 min. The number of 
erythrocytes before and after filtration was counted and the filtration rate was 
calculated as follows:  
Number of erythrocytes after filtration/number of erythrocytes before filtration x 100 
 = filtration rate in % 
 
2.2.4.4 Infected erythrocytes deformability assay  
The deformability of infected erythrocytes was also determined. The P. falciparum 
strain FCR3 was used to infect erythrocytes from an individual bearing the insertion 
genotype +/+ and erythrocytes from an individual with the deletion genotype -/-. The 
cultures were cultivated for at least three weeks and then synchronized by treating 
the culture two times with sorbitol.  
At a parasitemia of at least 3%, the trophozoite stages were enriched by treating the 
culture with gelatine as described (2.2.2.6). The enriched infected erythrocytes were 
then diluted 1:250 with the cell pack buffer and 30 µl of the suspension was added to 
the centrifugal unit and filtered as described above. The number of erythrocytes 
before and after filtration was determined with a cell viability analyser and the number 
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of infected erythrocytes before and after filtration was determined by flow cytometry 
as described in 2.2.3.6. The filtration rate of infected erythrocytes was then 
calculated:  number of infected erythrocytes after centrifugation/ number of infected 
erythrocytes before centrifugation x 100 
 
 
 
 
 
 
 
2.2.5 Western blot analysis 
 
Western blot analysis was used to determine the protein level of PdxK in 
erythrocytes. Erythrocytic spectrin was used as a loading control. 
 
 
2.2.5.1 Erythrocyte preparation  
For the Western blot analysis of the human erythrocytic pyridoxal kinase, 7 ml 
venous blood from individuals bearing the various genotypes: +/+, +/- and -/- was 
collected into heparin tubes. The blood was transferred into 15 ml falcon tubes and 
centrifuged at 4000 rpm for 10 min at room temperature. The plasma fraction and 
buffy coat was discarded. The erythrocytes were then washed twice with ringer 
solution and stored in an equal volume of Ringer solution at 4°C.  
 
 
2.2.5.2 Erythrocyte count and lysis 
 
The erythrocytes were centrifuged at 2000 rpm for 5 min and the ringer supernatant 
was discarded. 5 µl of erythrocytes was added to 10 ml ringer solution (1:2000), the 
suspension was analyzed with a cell viability analyzer (Vi-Cell, Beckman coulter) and 
the number of erythrocytes per ml was determined. Equal amounts of erythrocytes 
were lysed with 6 x equal volume of water (1:6 dilution). The lysates were stored at -
80°C. 
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2.2.5.2.1 Cell viability analyzer (Vi-Cell, Beckman coulter) 
The cell viability analyzer automates the widely accepted trypane blue dye exclusion 
method to assess cell viability. This is based on the fact that when cells die, their 
membranes become permeable, thereby allowing the uptake of the dye. As a result 
the dead cells become darker than the viable cells. 500 µl of the cellular suspension 
is aspirated, mixed with trypane blue and is pumped to the flow cell for imaging. The 
cells are imaged during measurement. The total number of cells per ml, the number 
of viable cells per ml and the percentage of viable cells are automatically determined. 
. 
 
2.2.5.3 SDS Polyacrylamide gel electrophoresis 
The erythrocyte proteins were resolved on an SDS polyacryamide gel. A 10% 
resolving SDS gel was prepared with the following components: 
3.3 ml 30% acrylamide/bis solution 
2.5 ml 1.5 M Tris-HCL, pH 8.8 
4 ml     H2O 
100 µl 10 % SDS 
100 µl 10 % APS 
10 µl  TEMED → total volume of 10 ml, was used for casting two gels. 
 
The gels were quickly cast between two glass plates of the Mini-Protean 3 Cell with a 
spacing of 1mm. The gel was allowed to polymerize for 2 hours.  After polymerization 
of the resolving gel, a 5 % stacking gel was prepared with the following components: 
830 µl   30 % acrylamide/Bis solution 
630 µl   1 M Tris pH 6.8 
50 µl     10 % SDS 
50 µl    10 % APS 
10 µl     TEMED 
3.4 ml   H2O → total volume of 5 ml was used for casting two gels above the 
resolving gel.  
The gel was allowed to polymerize for 30 min. 
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2.2.5.3.1 Denaturation of protein samples 
10 µl of the erythrocyte lysate sample was mixed with an equal volume of SDS 
sample buffer (2x) and the sample was heated for 5 min at 90°C. The protein marker 
was also heated for 5 min. 
10 µl of each sample and 7 µl of the marker were loaded onto the gel. The 
electrophoresis was run at 200 V for 1 h in 1 x SDS running buffer. 
Two gels were run parallel, one of the gels was blotted and the other was 
Commassie stained. 
 
 
 
 
2.2.5.3.2 Commassie blue staining 
At the end of electrophoresis one of the gels was immediately stained in a 
Commassie blue solution by incubating for at least 2-3 hours on a shaker. The gel 
was then destained by incubating the gel in a destain solution for at least 1 hour and 
changing the solution every 20 min. 
 
 
2.2.5.4 Blotting (Semi-dry) 
The gel was blotted on a PVDF transfer membrane with a pore size of 0.45 µM. 
Before blotting, the membrane was cut according to the gel size, shortly soaked in 
methanol and then in transfer buffer for at least 20 min. 8 layers of Whatman paper 
were also cut according to the gel size and soaked in the transfer buffer for at least 
20 min. 4 layers of Whatman paper were carefully placed on the plate of the blotting 
machine (Bio-Rad Trans-Blot Semi dry) and air bubbles were rolled out. The 
membrane was then placed on the Whatman paper stack, the gel was carefully 
placed on top of the membrane and then 4 layers of Whatman were placed on top 
and air bubbles were again rolled out. The gel was blotted onto the membrane at 24 
V for 50 min. After blotting the membrane was incubated overnight in 5 % milk at 
4°C. 
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2.2.5.5 Detection 
 
The following day the membrane was washed for 10 min in TBST buffer. The 
polyclonal anti hPdxK antibody and anti α-spectrin was diluted 1:1000 in 10 ml 1 % 
milk. The upper part of the membrane was carefully cut and incubated with the anti 
spectrin antibody for 2 h. The rest of the membrane was incubated with the anti-
hPdxK solution also for 2 h. After incubation the membranes were washed for 10 min 
(3 times) with TBST buffer. The secondary antibody anti-rabbit was diluted 1:2500 in 
10 ml 1 % milk. The membranes were then incubated with the secondary antibody for 
1 h. At the end of the incubation, the membranes were washed 3 times for 10 min 
with TBST buffer. 
Bound antibodies were detected by incubating the membrane with the ECL detection 
reagent which comprises of detection reagent 1 and 2 mixed in ratio of 1:1, for 5 min. 
The membranes were quickly transferred with its protein side facing up into a 
development folder in a plastic bag. 
 In the dark room an Amersham HyperfilmTM   ECL, a high performance 
chemiluminescene film was cut to the appropriate size and exposed to the membrane 
for 10 s, 30 s, 1 min and 5 min. The exposure time was sometimes increased 
depending on the strength of the signal. The film was then passed through a 
developing machine. 
 
 
 
2.2.5.6 Blot quantification 
 
The western blots were quantified with the ImageJ software. The integrated densities 
of each band was analyzed and correlated with the protein level of the sample. 
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2.2.6 Erythrocytic pyridoxal kinase activity assay 
 
The erythrocytic pyridoxal kinase activity of individuals homozygous for the insertion 
(+/+), heterozygous for the insertion (+/-) and individuals homozygous for the deletion 
(-/-) was determined. 
2.2.6.1 Preparation of erythrocytes 
 
To determine the activity of the erythrocytic pyridoxal kinase, 7 ml venous blood was 
collected in lithium heparin tubes from individuals bearing the various genotype 
+/+,+/- and -/-.  The blood from each individual was transferred into a 15 ml falcon 
tube and centrifuged for 10 min at 4000 rpm. The plasma and the white blood cell 
fraction were discarded and the erythrocytes were washed twice with an equal 
volume of Ringer solution. The erythrocytes were stored in an equal volume of Ringer 
solution over night at 4°C. 
 
2.2.6.2 Erythrocyte count 
 
The erythrocyte solution was centrifuged at 2000 rpm for 5 min and the supernatant 
was discarded. To determine the numbers of erythrocytes per ml for each individual, 
5 µl of erythrocytes were added to 10 ml of Ringer solution (1:2000 dilutions) and this 
suspension was analyzed with the cell viability analyzer. 
 
2.2.6.3 Pyridoxal kinase assay 
 
8 x 109 erythrocytes/ml from each individual were lysed by diluting the appropriate 
volume of erythrocytes with 10 volumes of lysis buffer in a 50 ml falcon tube and 
incubation on ice for 20 min.  To obtain a membrane free cytoplasmic fraction,  
The erythrocyte lysate was centrifuged at 10000rpm for 3 0min at 4°C. 
The reaction mix was added to a 15 ml falcon tube. A master mix for 6 samples was 
prepared. 
Pyridoxal kinase reaction mix: 
1, 35 ml reaction buffer 
50 µl 40 mM MgCl2
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100 µl 160 µM pyridoxal hydrochloride 
100 µl 200 mM Na2ATP 
400 µl erythrocyte lysate 
1 ml of the reaction mix was added to a dark eppendorf tube and incubated at 37°C 
under constant shaking at 400 rpm. To ascertain the amount of PLP that is formed 
per min, the samples were measured after 5, 15, 30, 60 and 90 min of incubation. It 
is important for the detection of the product pyridoxal 5-phosphate (PLP) to deprive 
the samples of haemoglobin. Therefore, 1 ml of the PdxK reaction mix was 
immediately transferred into a Millipore centrifugal filter unit and centrifuged for 15 
min at 3100 rpm and 10°C (T0). The membrane of the Millipore centrifugal unit had a 
cut off of 30 KDa and therefore all proteins with a molecular weight above 30 KDa 
remained in the filter. The flow through was a clear solution and was transferred into 
a dark eppendorf tube and stored at -21°C. 
After the incubation time the reaction mix was deprived of haemoglobine by 
centrifugation at 3100 rpm for 15 min at 10°C using a Millipore centrifugal unit. The 
flow through was transferred to a dark eppendorf tube and stored at -21°C till further 
analysis. The PLP concentration after 3 h of incubation was also measured. 
 
 
 
2.2.6.4 Detection and quantification of pyridoxal 5- phosphate (PLP) 
 
The amount of pyridoxal 5-phosphate at T0 and the various incubation times was 
quantified for each sample. The samples were analysed at the central lab of the 
University Hospital Heidelberg. 
The method is based on High –Performance-Liquid-Chromatography (HPLC) with 
fluorescence detection. Before the analysis the samples were treated to convert 
pyridoxal 5-phosphate into a strong fluorescence derivate, 4-pyridoxic acid 5′-
phosphate.  After the HPLC separation the samples were then analysed with a 
fluorescence detector for quantification. 
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2.2.6.4.1 Workflow 
50 µl of cyanide containing derivatisation reagent (Chromsystems) was added to 100 
µl of the sample and shortly mixed. The samples were incubated for 20 min at 60°C 
in a water bath and then cooled in the refrigerator for 10 min. After centrifugation at 
13000 rpm for 5 min, the samples were ready for HPLC analysis. 
50 µl of the sample was injected into HPLC system consisting of a RP 18 column 
(Chromsystems) and a fluorescence detector. The PLP derivate was excited at 320 
nm and its fluorescence was detected at 415 nm. 
 
 
 
 
 
2.2.7  Pyridoxal 5-phosphate content of parasites and  
          erythrocytes in culture 
 
To determine the parasitic content of pyridoxal 5-phosphate, a 3D7 strain of P. 
falciparum was cultivated in erythrocytes of the +/+, +/- and -/- genotypes for a period 
of at least four weeks.  Parallel cultures were also set up with pyridoxine depleted 
medium. The cultures were synchronized by treating two times with sorbitol as 
described in 2.2.2.7. 
To determine the PLP content of the parasite after culturing in erythrocytes from 
individuals bearing the various genotypes, trophozoite stages at a parasitemia of 4 % 
were used.  
 
2.2.7.1  Erythrocyte and parasite lysis 
 
The cultures with trophozoites were transferred into 15 ml falcon tubes and 
centrifuged at 2000 rpm for 3 min. The supernatant was discarded and the 
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erythrocyte pellet was adjusted to the same parasitemia by diluting with uninfected 
erythrocytes bearing the respective genotype.  
The number of erythrocytes/ml from each culture was determined with the cell 
viability analyser. Equal amounts of erythrocytes were lysed. 
 
2.2.7.1.1 Saponin lysis of erythrocytes 
Erythrocytes were lysed by adding 13 volumes (14 ml) of a 0.2% saponin solution. 
The suspension was vortexed and shaked vigorously and then incubated on ice for 
20 min. The suspension was centrifuged at 4000 rpm for 5 min. 1 ml of the 
erythrocytic lysate supernatant was transferred to an eppendorf tube and stored at      
-21°C. The rest of the supernatant was discarded. 
2.2.7.1.2 Parasite lysis 
The parasitic pellet was washed twice with PBS by centrifugation at 14000 rpm for 1 
min to remove all traces of the erythrocyte lysate. The parasite pellet was then 
resuspended in 500 µl of cold RIPA buffer, vortexed and stored at -21°C. 
 
2.2.7.2  Detection of pyridoxal 5-phosphate 
For the detection of PLP, the parasitic and erythrocytic lysate were deprived of 
haemoglobin and other high molecular weight proteins by centrifugation with the 
Millipore centrifugal filter unit (cut off 30KDa) at 3100 rpm for 15 min. The clear flow 
through was transferred into dark eppendorf tubes and sent to the central lab of the 
University Hospital Heidelberg. The PLP content of each sample was analyzed by 
HPLC and fluorescence detection as described in 2.2.6.4. 
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Figure 2.2.7: Workflow for determining the PLP content of the parasite and 
erythrocytes in culture.  
Parasite pellet  wash twice with PBS        lysis      
          Millipore centrifugal unit        Central Lab         PLP content 
    
 
 
Erythrocyte lysate         Millipore centrifugal unit       Central Lab         PLP 
content 
The diagram shows the result of saponin lysis of infected erythrocytes after centrifugation at 
4000 rpm for 5 min. The dark parasite pellet is at the bottom of the tube and the erythrocyte 
lysate is the supernatant. The erythrocyte lysate and the parasite lysate were sent to the 
Central lab for the quantification of PLP 
 
 
 
 
 
2.2.8  Electron microscopy 
 
To investigate the morphology of the parasite when cultured in erythrocytes bearing 
the deletion genotype (-/-) and insertion genotype (+/+), we employed the techniques 
of electron microscopy. 
The electron microscope (EM) uses a particle beam of electrons to illuminate the 
specimen and create a magnified image of it. The electron microscope has a greater 
resolving power (magnification) than a light-powered optical microscope, because it 
uses electrons that have wavelengths about 100,000 times shorter than visible light 
(photons), and can achieve magnifications of up to 1,000,000 x, whereas light 
microscopes are limited to 1000 x magnification. The electron microscope uses 
electrostatic and electromagnetic "lenses" to control the electron beam and focus it to 
form an image. These lenses are analogous to, but different from the glass lenses of 
an optical microscope that forms a magnified image by focusing light on or through 
the specimen. 
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2.2.8.1 Tokuyasu method 
 
It is often important to section cells and tissues before microscopic examination. 
However, biological materials are usually fragile and optimal sections cannot be 
obtained without embedding the sample in a supporting medium 
Ultra thin sections of the samples were therefore prepared according to the method 
proposed by Tokuyasu, 1980. 
 
 
2.2.8.1.1 Selection of trophozoites using magnetic cell sorting    
(MACS) 
P. falciparum strain 3D7 was cultured in T 75 flasks using erythrocytes from 
individuals bearing the +/+ and -/- genotype. The parasites were cultivated for a 
period of at least 4 weeks. The cultures were synchronized by treating 2 times with 
sorbitol. At a parasitemia of at least 4 % the trophozoite stages were enriched using 
the MACS column (Ahn, Shin et al. 2008). This method is based on the principle that 
haemozoin which is accumulated in late blood stages, posses paramagnetic 
properties. Trophozoites and later blood stages therefore remain in the MACS 
column while uninfected erythrocytes and ring stages flow through. 
The column is connected with a 3-way stopcock, with which the column can be 
opened or closed. A 10 ml syringe was filled with 2 % BSA/PBS and connected to the 
left opening of the 3-way stopcock. The column is loaded with 2 % BSA/PBS by 
carefully pushing the syringe and filling up to 10 mm above the column matrix. The 3-
way stopcock was closed and the column incubated for at least 5 min. The syringe 
was refilled with 2 % BSA/PBS and reconnected to the column.  
The parasite cultures were then centrifuged at 2000 rpm for 3 min. The pellet was 
resuspended in 4 ml of 2 % BSA/PBS.  The column was added to the magnet block 
.After eluting the BSA/PBS solution on the column, the parasites were then loaded 
onto the column and allowed to migrate into the column. Some 2 % BSA/PBS was 
added and the cells were allowed to sediment by quick opening of the stopcock, 
allowing a flow rate of 1 drop every 3 seconds. The column was washed with 
BSA/PBS. The bound parasites were then eluted by taking the column out of the 
magnet, opening the 3 way stopcock and collecting the parasites in a falcon tube.  
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Figure 2.2.8: Schematic drawing of the MACS column. 
 
 
2.2.8.1.2 Cell fixation and embedding 
The parasite elute was centrifuged at 2000 rpm for 3 min and the pellet was 
resuspended in 2 ml of PBS. 2 ml of Fix 1 was added to the cell suspension and 
allowed to incubate for 5 min. The suspension was centrifuged at 2000 rpm for 3 min 
and the supernatant was discarded. The pellet was resuspended in 2 ml of Fix 2 and 
allowed to incubate for 1h. 
The suspension was centrifuged and the supernatant was discarded. The pellet was 
washed twice with 10 ml PBS and rinsed with 2 ml of 50 mM glycine for 10 min. The 
cell suspension was transferred to a 2 ml eppendorf tube and centrifuged. The 
supernatant was discarded and the pellet was suspended in 1 ml of 10-12 % 
gelatine. 
The suspension was incubated for 5 min at 37°C, then centrifuged for 30 s and the 
supernatant was discarded. The pellet was incubated on ice for 30 min. With a 
flattened tooth pick the pellet was pushed out of the tube, put in a drop of sucrose 
and cut into tiny cubes of appropriate size on ice. The cubes were put into a suitable 
container with 2.3 M sucrose and put on a turning wheel in the cold room over night. 
Sucrose prevents the formation of ice crystals when freezing the samples. After the 
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infiltration with sucrose the cubes were put on a specimen holder (small metal pins) 
and frozen immediately in liquid nitrogen. 
 
2.2.8.1.3 Cryo-sectioning 
The instructions of the microtome manual were followed to install the knife and 
cooling down the microtome to the desired temperature of -90 to -100°C. When the 
microtome had been adjusted to the desired temperature, the pin (sample holder) 
with the frozen sample was transferred to the cryo-chamber and fixed properly in the 
microtome arm. The sample block was trimmed with a glass knife by cutting semi thin 
sections. After trimming, the glass knife was removed and replaced with a diamond 
knife which was then used for sectioning. Thin sections of 60nm and semi thin 
sections of 100 nm were made.  
The sections were retrieved with a droplet of 2.3 M Sucrose, the pick-up droplet in a 
stainless steel loop mounted on a 15 cm long bamboo sticks. The sections were put 
on grids and the grids were transferred to 2 % solid gelatine plates and stored at 4°C. 
 
 
 
2.2.8.1.4  Contrast staining 
The sections were stained for contrast and supported by polymers in order to prevent 
drying artefacts. The grids were incubated in uranyl acetate/methyl cellulose (UA/MC) 
mixture which is composed of 4 % uranyl acetate and 2 % methyl cellulose in a ratio 
of 1:9 for 5-10 min. The grid was picked with a wire loop. The loop and the grid were 
tilted to an angle of 45-60° and the side of the loop was touched to an absorbing filter 
paper to remove excess UA/MC. The grids were then allowed to dry at room 
temperature. 
 
2.2.8.1.5 Microscopy 
The samples were analysed with the TECNAI F30, 300kv FEG, FEI at the electron 
microscope core facility of the EMBL in Heidelberg. This microscope is a tomography 
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microscope and is mostly devoted to acquiring tilt series from embedded samples. It 
is also a cryoEM microscope that allows the analysis of frozen hydrated sections. 
 
2.2.9 Quantitative real time PCR 
 
Quantitative real time PCR was employed to investigate the fold change in mRNA 
levels of two enzymes PfPdx1 and PfPdxK, involved in the parasitic metabolism of 
vitamin B6. 
 
2.2.9.1 Isolation of mRNA from P.falciparum 
 
P. falciparum was cultivated in erythrocytes from individuals bearing the +/+ 
genotype, +/- genotype and -/- genotype. The parasites were cultured with complete 
RPMI medium and also in medium depleted of pyridoxine using T75 flasks. The 
cultures were cultivated for a period of at least 4 weeks. Cultures were synchronized 
by treating 2 times with sorbitol as described in 2.2.2.7. Trophozoite stages at a 
parasitemia of about 3-5 % were used fro the isolation of mRNA. The cultures were 
transferred to 50 ml falcon tubes and centrifuged at 2000 rpm for 3min. The 
supernatant was discarded and 10 ml of Roche mRNA stabilization solution was 
added to the pellet. The samples were stored at -21°C until mRNA purification. The 
isolation of the mRNA was then performed with the mRNA Isolation Kit for blood and 
bone marrow (Roche, Mannheim, DE). The instructions were followed as indicated in 
the protocol of the manufacturer. 
 
2.2.9.2 DNase treatment  
 
The mRNA isolation kit does not include a DNase digestion step during purification. 
To avoid contamination of mRNA with genomic DNA which could lead to false 
results, the samples were therefore treated with Dnase. The DNase treatment was 
carried out with the Turbo DNA free kit and the instructions of the manufacturer were 
followed. 
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2.2.9.3 Reverse Transcription (cDNA synthesis) 
 
mRNA was transcribed into cDNA with the RETROscript Kit from Ambion. Oligo d’T 
primers were used to initiate cDNA synthesis and the instructions were followed as 
indicated in the protocol by the manufacturer. 
 
 
2.2.9.4 Real time PCR 
 
The changes in mRNA levels of pfpdx1 and pfpdxk when the parasite was cultured in 
erythrocytes bearing the various genotypes and in medium depleted of pyridoxine 
was analyzed with real time PCR using a Sybr green based assay.  
Primers were designed for both genes using the primer express 3.0 software from 
ABI. 
 
The reaction mix with a total volume of 25 µl was prepared as follow: 
3 µl   cDNA 
12.5 µl  2 x Sybr power master mix 
0.025 µl  forward primer 
0.025 µl reverse primer 
9.45 µl H2O  
A negative control containing only H2O and mRNA to exclude gDNA contamination 
was run on each plate.  
All measurements were run as duplicates on each plate. The PCR was run on an ABI 
7500 cylcer machine with the following conditions: 
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Stage Repetitions Temperature Time 
1 1 95°C 5 min 
2 40 95°C 
58°C 
60°C 
15 sec 
15 sec 
45sec 
3 (dissociation ) 1 95°C 
60°C 
95°C 
15 sec 
1 min 
15 sec 
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3 Results 
 
3.1 Screening individuals for the 8 bp insertion in the   
promoter region of the pdxK gene 
To investigate the effect of lowered erythrocytic pyridoxal kinase activity on P. 
falciparum in an in vitro culture system, I had to screen individuals for the 
polymorphism in the promoter region of the pdxk gene (Flanagan and Beutler 2006). I 
established two PCR based methods for this purpose. The first being a PCR using 
allele specific primers to detect the 8 bp insertion (Figure 3.1) and the second a PCR 
amplifying a small fragment of 80 bp and detecting the difference in size on a 
metaphor gel (Figure 3.2). 
 
Figure 3.1:  Allele specific PCR. A: Schematic drawing of the allele specific PCR. B: A 
nested PCR with allele specific primers was carried out using a 700 bp amplified fragment as 
template. The PCR was carried out in two separate reactions using a forward primer with the 
insertion (+) and without the insertion (-) respectively. 
 
Figure 3.1B shows the result of a nested PCR. + represents the reaction with the 
insertion forward primer and – the reaction with the forward primer without the 
insertion. Sample 19 represents a heterozygote since a fragment was amplified in 
both reactions. Sample 20 is an individual who is homozygous for the deletion as I 
could only observe a band in the - reaction. Sample 15 and 18 are individuals who 
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are homozygous for the insertion event as the reaction was only positive with the 
insertion forward primer. The positive clones for the insertion (K+) and deletion event 
(K-) were always used for controls in each PCR reaction and a H20 sample (-) as an 
absolute negative control for the PCR reaction 
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3.1.1 Screening Caucasians for the 8 bp insertion in the promoter 
region on the pdxk gene 
Applying the PCR with allele specific primers (Figure 3.2), I screened 42 individuals 
resident in Heidelberg, Germany, for the 8 bp insertion in the promoter of the pdxk 
gene. These individuals were all Caucasians. 10 individuals were homozygous for 
the insertion event (+/+), 30 were heterozygous (+/-) and only 2 individuals were 
homozygous for the deletion event (-/-) (Table 3.1).  
This gave an allele frequency of 66.2% for the insertion allele (+) and 33.8 % for the 
deletion allele (-). In all, I found a genotype distribution among these individuals of 22 
% for insertion event (+/+), 73 % heterozygotes (+/-) and 5 % for the deletion event 
 (-/-) (Fig.3.3) 
   
3.1.2 Screening east Africans for the 8 bp insertion in the promoter 
region of the pdxk gene 
Genomic DNA samples from 33 individuals resident in Kilifi, Kenya were also 
screened for the 8 bp insertion using the allele specific PCR. All individuals were 
Africans. 2 individuals were homozygous for the 8 bp insertion event (+/+), 22 were 
heterozygotes (+/-) and 9 individuals were homozygous for the deletion event (-/-) 
(Table 3.1). I calculated an allele distribution of 34.09% for the insertion allele (+) and 
65.9% for the deletion allele (-). We had a genotype distribution of 6.06% for the 
insertion event (+/+), 66.6% for the heterozygotes (+/-) and 27.2% for the deletion 
event (-/-) (Fig 3.3) 
 
Table 3.1: Genotype distribution among Caucasians and Africans 
Race number of individuals 
screened 
+/+ +/- -/- 
Caucasians 42 10 30 2 
East Africans 33 2 22 9 
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The results of my PCR screen showed clearly that more individuals were 
homozygous for the deletion event (-/-) among the African population as compared to 
the Caucasians from Heidelberg. In both cases heterozygotes were the highest 
numbers. Only two individuals were homozygous for the deletion event -/- among 42 
Caucasians from Heidelberg whereas 9 had the -/- genotype among 33 individuals 
from Kenya. The genotype distribution in percent among the two races is shown in 
figure 3.3 
 
 
 
Figure 3.3: Genotype distribution of the 8 bp insertion allele among Caucasians and 
Africans. 45 Caucasians and 33 Africans were screened for the 8 bp insertion in the 
promoter region of the pdxk gene. 
 
 
 
 
 
 
3.1.3 Sequencing the promoter region of the pdxk gene 
 
To verify the results of my PCR screen, I sent in some of the 700 bp PCR fragments 
for sequencing. Sequencing confirmed the results of my PCR screen which showed 
that the allele specific PCR was reliable.  
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3.1.3.1 In/Del event in the promoter region of the pdxk gene 
Sequencing the 700 bp fragment amplified from genomic DNA of 23 individuals from 
Heidelberg and 9 from Kilifi followed by aligning the sequences with the Bioedit 
software revealed that there is another In/Del event of 7 bp in the promoter region of 
the pdxK gene. It was a 4 times repeat of the sequence 5´GGGGCGC 3´ which is 
located at -442 of the ATG and about  -130 bp of the known 8 bp insertion (figure 3.5) 
It was not possible to get clean sequence readouts for heterozygotes for both In/Del 
events (figure 3.4). However when the chromatogram is studied carefully, it is 
possible to read the single sequences 
 
 
p
Figure 3.4: Sequence c
heterozygote sequence.
 sequence overla 
hromatograph in the region of the 7 bp In/Del event. A: 
 B: homozygote sequence (-/-). 
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Figure 3.5: Sequence alignments. Sequences of homozygotes were aligned with the 
Bioedit software. Aligning sequences displayed two In/Del events in the promoter region of 
the pdxk gene. It shows the 8 bp insertion which has already been reported and the 7 bp 
insertion which is at - 442 bp of ATG.  
 
 
 
3.1.3.2 MatInsepector analysis of the 7 bp In/Del event 
As the 7 bp In/Del event in the promoter region has not been reported before, I 
decided to explore if this polymorphism could also have an effect on the transcription 
of the pdxk gene. Using the MatInspector software, I examined if the 7 bp sequence 
5´GGGGCGC3´ is a binding site for transcription factors. Feeding the sequence 
around the region of interest into the program showed that the repeat GGCGCGG 
which is CCGCGCC on the minus strand is a recognition motif of the RNA 
polymerase II transcription factor IIB (Table 3.2). 
The transcription factor IIB (TFIIB) plays a critical role in the assembly of the RNA 
polymerase II pre-initiation complex. TFIIB makes sequence specific DNA contacts 
both upstream and down stream of the TATA box. These specific sequences have 
been defined as BREs, one upstream BRE (BREu) and one down stream BRE 
(BREd) of the TATA box. The BREu consensus sequence is 5´-G/C-G/C-G/A-C-G-C-
C-3´. The BREu may act as a positive or negative element in transcriptional 
regulation (Deng and Roberts 2006). BRE sequences are found in bidirectional and 
non-bidirectional promoters (Yang and Elnitski 2008) 
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Table 3.2: MatInspector analysis of the 7 bp repeat.  Analysis of the 7 bp sequence 
GGCGCGG (CCGCGCC, minus strand) gave the highest hit score of 1 for the RNA 
polymerase II transcription factor II B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I could only detect the presence of the 7 bp In/Del event by sequencing the 700 bp  
amplified PCR fragment. It was not possible to apply allele specific PCR to screen for 
this polymorphism.  The 7 bp sequence CCGCGCC (- strand) is a binding sequence 
for the TFII B. It is not clear whether/how the presence or absence of this sequence 
could affect the transcription of the pdxk gene. I sequenced 22 individuals from 
Heidelberg, Germany and 9 from Kilifi, Kenya. I observed that among the individuals 
from Heidelberg, those bearing the +/+ genotype for the 8 bp insertion event were 
homozygous for the deletion genotype (-/-) for the 7 bp event, heterozygotes for the 8 
bp insertion event (+/-) were also heterozygous for the 7 bp event and one individual 
bearing the deletion genotype (-/-) for the 8 bp event had the insertion genotype (+/+) 
for the 7 bp event.The second individual bearing the deletion genotype (-/-) for the 8 
bp event was heterozygous for the 7 bp event. 
Among the Africans, 3 individuals with the deletion genotype (-/-) for the 8 bp event 
also bore the -/- genotype for the 7 bp event. 2 individuals bearing the +/+ genotype 
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for the 8 bp event had the -/- genotype for the 7 bp event and 1 individual with the +/- 
genotype for the 8 bp event bore the -/- genotype for the 7 bp event. 
This result is presented in table 3.3. 
 
 
Table 3.3: Genotype distribution for both In/Del events in the promoter region of the  
     pdxK gene 
       
Individuals 8bp insertion 7bp insertion 
Caucasians             1 +/+ -/- 
                                 2 +/+ -/- 
                                 3 +/+ -/- 
                               4 +/+ -/- 
                                 5 +/+ -/- 
                                 6  +/+ -/- 
                                 7 +/+ -/- 
                                 8 +/+ -/- 
                                 9 +/- +/- 
                                10 +/- +/- 
                                11 +/- +/- 
                                12 +/- +/- 
                                13 +/- +/- 
                                14 +/- +/- 
                                15 +/- +/- 
                                16 +/- +/- 
                                17 +/- +/- 
                                18 +/- +/- 
                                19 +/- +/- 
                                20 +/- +/- 
                                21 -/- +/+ 
                                22 -/- +/- 
Africans                    1 +/+ -/- 
                                  2 +/+ -/- 
                                  3 +/+ -/- 
                                  4 +/- +/- 
                                  5 +/- -/- 
                                  6 -/- -/- 
                                  7 -/- +/+ 
                                  8 -/- -/- 
                                  9 -/- -/- 
 
 
 
The presence or absence of the 7 bp In/Del event did not correlate with the PdxK 
protein level in erythrocytes or the erythrocytic activity of the enzyme. 
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3.2 Western blot analysis  
It has been proposed that the presence of an 8 bp insertion in the promoter region of 
the pdxk gene leads to enhanced transcription of the gene. It is proposed that there 
is a 4 fold increase in transcription of the gene (Flanagan and Beutler 2006). It is not 
possible to detect mRNA levels in matured erythrocytes. Since an increased level of 
the transcripts should correlate with an increased amount of the protein, I decided to 
compare the protein level of PdxK in erythrocytes of individuals bearing the 
genotypes +/+, +/- and -/-. The number of erythrocytes/ml was determined for each 
individual (Table 3.4) and equal amounts were lysed for Western blot analysis.  
Samples were resolved on an SDS gel and stained with Commassie blue (Figure 3.6) 
for visual inspection. The Commassie blue stained gel showed that the samples had 
equal amount of proteins. 
 
 
 
Table 3.4:  Erythrocyte counts obtained with the cell viability analyser. The number of 
erythrocyte per ml of individuals with the various genotypes was determined. The washed 
erythrocytes were diluted 1:2000 and analysed with the cell viability analyser. Equal amounts 
of erythrocytes per individual were lysed for western blot analysis. 
 
Individual  Genotype Total cells/ml x dilution Volume lysed (µl) 
1 +/+ 3.6   x  106 7.2   x 109 140
2 +/+ 1.82 x 106 3.64 x 109 276.9
3 +/+ 1.36 x 106 2.72 x 109 370
4 +/+ 2.10 x 106 4.20 x109 120
5 +/+ 1.60 x 106 3.30 x109 315
6 +/- 5.04 x 106 10.08 x109 100
7 +/- 2.98 x 106 5.96 x 109 169
8 +/- 2.02 x 106 4.40 x 109 249.5
9 +/- 3.14 x 106 6.28 x 109 160
10 +/- 3.86 x 106 7.72 x109 130.5
11 +/- 4.7   x 106 9.40 x 109 107.2
12 +/- 4.9  x 106 9.80 x109 102.8
13 -/- 5.02 x 106 10.04 x 109 100.3
14 -/- 3.36 x 106 6.72 x109 150
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Figure 3.6: Commassie stained gel of erythrocyte lysates.  Some of the erythrocyte 
lysate samples of various genotypes were stained with Commassie to detect the protein 
levels of the samples. The staining revealed that all samples had roughly the same amount 
of protein. 
 
 
 
Using Western blot analysis I could detect the erythrocytic PdxK by probing with a  
polyclonal antibody specific for the protein. Densitometric analysis of the blots 
revealed that the protein level of PdxK was significantly lower in erythrocytes from 
individuals bearing the deletion genotype (-/-) as compared to those of individuals 
bearing the +/- and +/+ genotypes (t test p value ++/-- :0.0097, +-/--: 0.024) 
I used erythrocytic α-spectrin as a loading control. Densitometric analysis of the blot 
showed that the protein level of spectrin was roughly the same in erythrocyte lysate 
of the various genotypes. The polyclonal rabbit anti-α-spectrin antibody used in the 
Western blot analysis of the erythrocytic α- spectrin, cross reacted with ß-spectrin 
band, which appears as the lower of the two bands in the western blot analysis. 
        
 
 
Figure 3.7:  Western blot analyses of the erythrocytic PdxK and α-spectrin. Equal 
amounts of erythrocytes from each individual were lysed for Western blot analysis A: hPdxK 
probing: Western blot of erythrocyte lysate of the various genotypes. The PdxK has a 
molecular weight of  40 KDa but is detected at a size between 55 and 72 KDa on an SDS gel 
(Kerry J.A 1986). Individuals bearing the deletion genotype had weaker bands as compared 
to those with the +/+ and +/- genotype. B: The α-spectrin band was detected at above 170 
KDa. The anti α-spectrin polyclonal antibody cross reacted with the ß-spectrin subunit (lower 
band). 
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Figure 3.8: Densitometric analysis of the individuals’ bands obtained by Western blot 
analyses.  A: The hPdxk Western blots were analysed with the imageJ software and the 
integrated densities of the bands were compared. Erythrocyte with the -/- genotype had lower 
levels of hPdxK as compared to levels in erythrocyte of the +/+ and +/- genotypes. B: The α-
spectrin levels in erythrocytes of various genotypes were also compared and the levels were 
roughly the same in the various samples. 
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3.3 Pyridoxal kinase activity 
 
After observing that the protein level of erythrocytic PdxK is lower in erythrocytes of 
individuals bearing the -/- genotype, I investigated if this observation correlates with 
the activity of the enzyme. It has been previously shown that the presence of the 
deletion event in the promoter of the pdxk gene leads to a lower activity of the 
enzyme in erythrocytes (Flanagan and Beutler 2006). I adapted the method as 
proposed by Kark J et al for the determination of PdxK enzymatic activity (Kark, Haut 
et al. 1982).  Equal amounts of erythrocytes were lysed (Table 3.5) and equal 
volumes of the lysate were added to the reaction mix (see material and methods). 
The erythrocytes used in this experiment were fresh and not older than a day to avoid 
an inhibited activity of the enzyme due to cell age. The amount of PLP (nmol/l) was 
analysed and quantified in the Central Lab of the University Hospital Heidelberg.  
Firstly, I measured the amount of PLP that is formed by the pyridoxal kinase of 
erythrocytes from individuals bearing the various genotypes after an incubation 
period of 3 hours. The individuals had different amounts of PLP at the onset of the 
experiment (T0). At the end of the 3 hour incubation time, I could measure a 
significant increase in the amount of PLP present in the reaction mix with lysate of 
erythrocytes with the various genotypes (Table 3.6) 
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Table 3.5: Erythrocyte count with the cell viability analyser. The amount of erythrocytes 
per ml of individuals bearing the various genotypes was determined. The erythrocytes from 
the individuals were highly viable.  Equal volumes of erythrocytes were lysed to determine   
pyridoxal kinase activity. 
 
Individual Genotype Total 
cells/ml 
Viable 
cells/ml 
Viability 
% 
x dilution factor 
cells/ml 
Volume 
lysed 
(ml) 
1 +/+ 2.57 x 106 2.57 x106      99,8% 5.14 x 109 1.55 
2 +/+ 2.88 x 106 2.88 x 106       97.9% 5.76 x 109 1.38 
3 +/+ 2.58 x 106 2.50 x 106       96.8% 5.10  x 109 1.55 
4 +/+ 3.32 x 106 3.17 x 106       95.5% 6.64 x 109 1.20 
5 +/+ 3.06 x 106 2.34 x 106       76.5% 6.12 x 109 1.30 
6 +/- 2.23 x 106 2.19 x 106       98.8% 4.46 x 109 1.79 
7 +/- 2.71 x 106 2.61 x  106       96.1% 5.40 x 109 1.47 
8 +/- 3.33 x 106 3.21 x 106       96.4% 6.60 x 109 1.20 
9 +/- 3.06 x 106 2.99 x 106       97.7% 6.12 x 109 1.30 
10 +/- 3.53 x 106 3.46 x 106       98.0% 7.06 x 109 1.13 
11 +/- 2.78 x 106 2.73 x 106       98.4% 5.56 x 109 1.43 
12 -/- 2.90 x 106 2.81 x 106       97.0% 5.16 x 109 1.37 
13 -/- 1.82 x 106 1.82 x 106       99.7% 3.64 x 109 2.19 
 
 
Table 3.6: Amount of PLP formed after 3 hours of incubation. The amount of PLP formed 
after 3 hours of incubation was measured for the various genotypes. There was a high 
amount of PLP formed after 3 hours of incubation (T1).  The experiment was conducted once. 
 
Individual Genotype           T0  
PLP (nmol/L) 
           T1
PLP (nmol/L) 
      T1 – T0
PLP (nmol/L) 
1  +/+ 15.4 753.5 738.1 
2 +/+ 9.4 391.7 382.3 
3 +/+ 5.1 648.6 643.5 
4 +/+ 3.1 518.4 515.3 
5 +/- 11.2 257.9 246.7 
6 +/- 5.7 420.4 414.7 
7 +/- 3.7 366.0 362.3 
8 +/- 8.3 529.3 521.0 
9 +/- 8.2 511.4 503.2 
10 +/- 24.4 533.7 509.3 
11 -/- 23.5 625.0 601.5 
12 -/- 9.0 505.9 496.9 
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There was only a weak correlation between the amount of PLP formed after 3 hours 
of incubation and the various genotypes. The amount of PLP formed by the PdxK in 
lysates of erythrocytes of the four tested individuals bearing the +/+ genotype varied 
significantly. It ranged from 382.3 nmol/L to 738.1 nmol/L with an average value of 
569.8nmol. The amount of PLP formed after incubation of lysates of the +/- 
genotypes also varied but was intermediate to that of the +/+ and -/- genotypes. Here 
in average 462.2nmol/L PLP was generated. The amount of PLP formed by the 
enzyme in lysate of erythrocytes of the two individuals with the -/- genotypes was with 
an average value of 459.2 nmol/L not significantly lower than that of +/+ genotype 
(Figure 3.9).  
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Figure 3.9: Amount of PLP formed after 3 hours of incubation. The amount of PLP 
formed after 3 hours incubation of the reaction mix with erythrocyte lysate of the various 
genotypes.  
 
 
 
 
3.3.1  Determining the amount of PLP formed per minute 
Since  the amount of PLP formed after 3 hours of incubation did not correlate with the 
expected hPdxK activity of the individual genotypes, I decided to measure the 
quantity of PLP that is formed per minute when lysate of the +/+ and -/- genotype 
were added to the reaction mix.  
For this experiment, equal amounts of fresh erythrocytes from an individual bearing 
the +/+ genotype and from an individual of the -/- genotype were lysed and added to 
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the reaction mix. The amount of PLP formed after 5, 15, 30, 60 and 90 min was 
determined.  
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Figure 3.10: PLP (nmol/L) formed over time.  The amount of PLP was determined at 
different time points as plotted on the x axis for the +/+ genotype and -/- genotype. The 
amount of PLP formed over time was higher for the +/+ genotype. The data is representative 
for two independent experiments. 
 
 
 
Figure 3.10 shows the result of the experiment in which I investigated the amount of 
PLP that is formed over time for the +/+ and -/- genotype. I observed that over time 
more PLP was formed in the reaction mix with the +/+ lysate than in the -/- reaction.  
I calculated a formation rate of 3.9 nmol/min for the +/+ reaction and 2.6 nmol/min for 
the -/- reaction. 
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Figure 3.11: PLP nmol/L formed per minute. The formation of PLP was followed over time.  
There was a significant difference between the amount of PLP formed per minute in the +/+ 
reaction and the -/- reaction. 
 
 
 
3.4 Pyridoxal 5- phosphate content of the erythrocytes of 
the various genotypes under in vitro culture conditions 
 
I investigated whether there were variations in the PLP content of erythrocytes with 
the various genotypes in an in vitro culture system.  To clarify if the presence or 
absence of pyridoxine in the culture medium has an effect on the PLP content of 
erythrocytes and parasites in culture, a parallel culture was held in the absence of 
pyridoxine in the medium. Erythrocytes were lysed with a saponin solution and 
parasites with RIPA buffer (see material and methods). The PLP content of the 
erythrocyte and parasite lysate was then measured in the central lab of the University 
Hospital Heidelberg. 
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Figure 3.12: Erythrocytic PLP content. The PLP content of erythrocytes in culture was 
determined. Erythrocytes of the different genotype were maintained in RPMI medium 
containing pyridoxine (+ Pyr) or depleted of pyridoxine (-Pyr). The error bars stand for the 
standard error of 3 independent measurements. The Y axis shows the amount of PLP in 
nmol/l and is plotted against the various genotypes in + Pyr and –Pyr medium on the x axis. 
 
 
 
 
Figure 3.12 shows the PLP content of erythrocytes of the different genotypes used in 
culture. The amount of PLP in erythrocytes of the +/+ and -/- genotype in RPMI 
medium containing pyridoxine was determined as well as that of erythrocytes of the 
different genotypes used in culture in pyridoxine depleted medium. 
 I observed that the amount of PLP was highest in erythrocytes of the +/+ genotype 
and in the presence of pyridoxine in the medium. I could not detect any significant 
difference in the amount of PLP in erythrocytes of the various genotypes in 
pyridoxine depleted medium. The PLP content in erythrocytes of the +/+ genotype in 
pyridoxine containing medium was significantly higher than that of erythrocytes of the 
+/- and -/- genotype. In contrast the PLP content of +/+ erythrocytes cultured in 
pyridoxine depleted medium was in similar range as that of erythrocytes of the +/- 
and -/- genotype. 
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3.5 In vitro growth experiments 
 
It has been shown that red blood cell polymorphisms that offer protection against 
malaria also affect the growth of the parasite in an in vitro culture system (Friedman 
1978; Roth, Raventos-Suarez et al. 1983; Fairhurst, Fujioka et al. 2003). To explore if 
the lowered erythrocytic pyridoxal kinase activity has an effect on the development of 
P. falciparum in an in vitro culture system, I conducted some growth experiments. 
The 3D7 strain of P. falciparum was cultivated in erythrocytes from individuals 
bearing the +/+, +/- and -/- genotype for the 8 bp insertion using medium with 
pyridoxine and depleted of pyridoxine. Parasitemia was determined by FACS 
analysis (Fig. 3.13) and Giemsa staining. 
 
 
Figure 3.13: Dot plots of FACS analysis during growth experiments. A upper panel 
shows the dot plots of the control samples. Erythrocytes of each genotype were stained with 
ethidium bromide. There was no fluorescence signal detected on the FL2 channel for each 
genotype which is represented as PE-A on the X axis. The forward scatter (FCS-A) is plotted 
on Y-axis. B, lower panel displays the dot plots of infected erythrocytes (iRBC) bearing the 
different genotypes on day 8 of the growth experiments. Fluorescent signals were detected 
on the FL2 channel after staining with ethidium bromide. 
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3.5.1 ABO Blood group and Hb variant test for growth experiments 
The outcome of malaria has been associated with ABO blood group. The blood 
group O has been suggested to protect against severe malaria (Fischer and Boone 
1998). It was therefore essential for the in vitro growth experiments to determine the 
blood group of the blood donors. Most individuals therefore that were screened for 
the 8 bp insertion were also tested for their blood group type. The majority of the 
individuals had the blood group A or O (Table 3.7).  All blood donors, who gave blood 
for the in vitro growth experiments, were Caucasians and had the same ABO blood 
group A with the exception of one donor who had the blood group type O. 
To exclude the effect of Haemoglobin variants such as HbAS, HbSS, and HbCC on 
the growth of the parasite, my blood donors were also tested for the different 
Haemoglobin variants. Each blood donor tested negative for the different 
Haemoglobin variants which was expected as these Hb variants are not common 
among Caucasians (Table 3.8) 
 
 
Table 3.7: ABO blood group of some of the individuals screened for the 8 bp insertion 
 
Individuals Blood group 
 1  O 
 2 A 
 3 A 
 4 A 
 5 A 
 6 A 
 7 B 
 8 A 
 9 A 
10 A 
11 B 
12 O 
13 A 
14 O 
15 A 
16 O 
17 O 
18 A 
19 A 
20 A 
21 A 
22 A 
23 AB 
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Table 3.8: Percentage of haemoglobin variants.  The percentage of the various 
haemoglobin variant was determined for the various blood donors. The results are in 
accordance with what is expected of adult Caucasians. Hb AO 95%, HbA2 1.8 -3.2% and 
less than 1% for HbF (fetal Hb), HbS (sickle Hb) and HbC 
 
Individual Genotype Hb A0 Hb A2 Hb F Hb S Hb C 
1 +/+ 95.5% 2.3% < 1% < 1% <1% 
2 +/- 94.7% 2.8% < 1% < 1% < 1% 
3 -/- 94.7% 2.8% < 1% < 1% < 1% 
 
 
Under standard in vitro cell culture conditions, parasites were able to grow in 
erythrocytes from individuals bearing the deletion genotype (-/-). 
In a set of three representative growth experiments, the mean parasitemia in 
erythrocytes of the -/- genotype was about half of that in erythrocytes of the +/+ and 
+/- genotype after 8 days of culture (figure 3.14 A). The impaired growth phenotype 
was first observed after 8 days of culture. At the beginning of the experiement, 
infected erythrocytes (genotype unknown) were added to uninfected erythrocytes of 
the respective genotype in a ratio of 1:10. Thus 1/10 of the erythrocytes in culture 
were not of the respective genotype.  Eventually since the cultures were splitted 
every third day, only erythrocytes of the respective genotype were present in the 
culture.  
On day 16 e.g. we measured a parasitemia of 3.58% for the +/+, 3.45% for the +/- 
and 1.75% for the -/- culture (t test, p value ++/-- :0.0001, p value: +-/--: 0.0001) We 
estimated that the cumulative increase in parasitemia over time and the parasitemia 
in erythrocytes of individuals bearing the +/+ and +/- genotype was approximately 101 
higher than in erythrocytes of the -/- genotype (Figure 3.14 B). 
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Figure 3.14: In vitro growth experiments using erythrocytes of the various genotypes. 
A, shows the growth of the parasite in erythrocytes bearing the various genotype and in 
medium containing pyridoxine, B shows the cumulative increase in parasitaemia over time.  
C and D portray the growth of the parasite in pyridoxine depleted medium and correspond to 
A and B respectively.  The parasites were cultured for 20 days as represented on the X axis. 
The course of the parasitemia curves are due to the splitting of the cultures. The arrows 
indicate when the culture was splitted.  The data is representaitive for 3 independent 
experiments. Each experiment was conducted with triplicates. The error bars stand for the 
standard error with values of < 0.5%. 
 
 
 
3.5.2 Comparing parasitemia in pyridoxine depleted medium 
 
I observed the same growth phenotype when the parasite was cultivated in 
pyridoxine depleted medium (Figure 3.14 C and D). The mean parasitemia in 
erythrocytes of individuals bearing -/- genotype was also about half of that in 
erythrocytes erythroytes of the +/+ and +/- genotype after 8 days of culture. On day 
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16 for example, the parasitemia was significantly lower (t test, p value: 0.0001) in 
erythrocytes of the -/- genotype as compared to that of the +/- and -/- genotype. 
However, comparing the growth of the parasite when cultivated in erythrocytes 
bearing the same genotype using pyridoxine containing and pyridoxine depleted 
medium, revealed that the growth of the parasite is partially affected when cultured in 
pyridoxine depleted medium. The growth of the parasite was hindered in the absence 
of pyridoxine in the medium. On day 16, I measured parasitemias that were 
significantly lower in the pyridoxine depleted medium than in complete medium (t 
test, p value; +/+ +Pyr/-Pyr: 0.0008, +/- +Pyr/-Pyr: 0.0001, -/- + Pyr/-Pyr: 0.0001) 
This effect was most clearly seen when the parasite is cultivated in erythrocytes 
bearing the -/- genotype (Figure 3.15). 
 
 
Figure 3.15: In vitro growth experiments in pyridoxine depleted medium. The growth of 
the parasite when cultured in complete medium was compared to that in pyridoxine depleted 
medium. The erythrocytes were of the same genotype and the parasites were cultured for a 
period of 20 days as represented on the X axis (upper panel). On the lower panel the 
parasitemia on day 16 after culture in complete medium was compared to that of pyridoxine 
depleted medium. This data is representative for two independent experiments. 
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3.5.3 The growth of P. falciparum in erythrocytes of two unrelated 
individuals bearing the same genotype 
 
I also conducted the growth experiments with erythrocytes from two unrelated 
individuals bearing the +/+ and the -/- genotype. All individuals were Caucasians and 
had the blood group A with the exception of the second individual bearing the -/- 
genotype who had the blood group O. In each case the parasites showed the same 
impaired growth phenotype when cultivated in erythrocytes bearing the -/- genotype. I 
observed the same effect when the parasites were cultured in pyridoxine depleted 
medium (Figure 3.16). 
 
 
Figure 3.16: In vitro growth experiments using erythrocytes of unrelated two 
individuals bearing the same genotype. Parasites were cultured fro a period of 20 days 
and the parasitemia was determined by counting giemsa stained slides. The growth of the 
parasite was impaired in erythrocytes from both individuals bearing the deletion type as 
compared to those with +/+ genotype. The data is representative for 3 independent 
experiments. 
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3.5.4  Short term growth experiments 
 
In a short term growth assay, I followed up the growth of 4 different P. falciparum 
strains 3D7, FCR3, HB3 and Dd2 cultured in erythrocytes with the different 
genotypes. The parasites were cultured in RPMI complete medium. I determined 
parasitemia every day with FACS analysis for a period of 3 days. I could confirm my 
observations of the retarded growth phenotype in -/- erythrocytes for each P. 
falciparum strain. I also observed an intermediate growth phenotype for most strains 
with the exception of Dd2 when cultured in erythrocytes of the +/- genotype. 
The growth of the parasite was already impaired on day 1 of the experiment in 
erythrocytes of the -/- genotype. This can be explained by the fact that the parasite 
strains were precultivated for four weeks in erythrocytes of the various genotypes 
respectively. Therefore, at the onset of the short term growth experiment, only 
erythrocytes of the respective genotypes were present in the culture (see Material 
and Methods 2.2.3.7) 
 
 
 
Figure 3.17: Short term growth assays with different P. falciparum strains. Different P. 
falciparum strains 3D7, FCR3, HB3 and Dd2 were cultured in erythrocytes of the various 
genotypes +/+, +/- and -/- for a short period of 3 days. Each strain exhibited the impaired 
growth phenotype when cultured in erythrocytes of the -/- genotype. The data is 
representative for 2 independent experiments. 
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3.6 Expression analysis of pfpdx1 and pfpdxk following 
growth in erythrocytes of the various genotypes 
 
It has been shown that P. falciparum possesses a de novo synthesis pathway for 
Vitamin B6 (Fitzpatrick, Amrhein et al. 2007). For this purpose, it utilizes the two 
proteins PfPdx1 and PfPdx2. In order to synthesize PLP, Pdx1 and Pdx2 form a 
complex that acts as a glutamine amidotransferase with Pdx2 as the glutaminase and 
Pdx1 as the PLP synthase domain (Gengenbacher, Fitzpatrick et al. 2006). The 
parasite also has a functional pyridoxal kinase for the phosphorylation of B6 vitamers 
upon uptake and for the salvage of vitamin B6 (Wrenger, Eschbach et al. 2005) 
Since individuals homozygous for the deletion event in the promoter region of the 
pdxk gene have a lower level of the PdxK protein in their erythrocytes which is 
accompanied by a lower activity of the enzyme, it is therefore assumed that 
erythrocytes from individuals bearing this genotype would also have a lower level of 
PLP. It is possible that the parasite could respond to the low PLP levels in its 
erythrocytic environment by upregulating its own enzymes involved in vitamin B6 
metabolism. 
To examine whether this is indeed the case, I analysed the fold change in mRNA 
levels of two of the enzymes involved in vitamin B6 homeostasis of the parasite 
namely, PfPdx1 and PfPdxK, when the parasite was cultured in erythrocytes bearing 
the diverse hPdxK genotypes. For this experiment a 3D7 strain of P. falciparum was 
cultured in erythrocytes of the genotypes +/+, +/- and -/- genotypes for four weeks. 
Parasites were then synchronized, mRNA was isolated from trophozoite stages, 
reverses transcribed to cDNA and the mRNA levels of pfpdx1 and pfpdxk was 
quantified by real time PCR (see material and methods 2.2.7). To exclude 
contaminiation with genomic DNA, a negative control with mRNA was always run in 
parallel. Contaminiation with genomic DNA was never detected. The parasites grown 
in +/+ erythrocytes in the presence of pyridoxine in the medium were used as 
reference and the ß-tubulin gene was used as internal control. 
 
Figure 3.18 shows the results of the real time analysis of mRNA levels for the pfpdx1 
and pfpdxK genes. I observed an increase in mRNA levels of both genes when the 
parasites were cultured in erythrocytes of the -/- genotypes. For the pfpdx1 gene 
which is involved in de novo synthesis of vitamin B6, there was a slight but significant 
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increase in the mRNA levels when cultured in +/- and -/- erythrocytes as compared to 
that of the +/+ genotype. I detected a 2.7 fold change in pfpdx1 mRNA levels after 
cultivation in -/- erythrocytes and 1.8 fold change after cultivation in +/- erythrocytes (t 
test, p value -/-: 0.029, +/-: 0.029).  
There was also slight increase in mRNA levels of the pfpdxk gene when the parasite 
was cultured in erythrocytes of the +- and -/- genotype. I detected a 2.1 fold change 
in pfpdxk mRNA levels when parasites were cultured in -/- erythrocytes and a 1.58 
fold change when cultured in +/- erythrocytes (t test, p value -/-: 0.031). The increase 
in mRNA levels of this gene following culturing in +/- erythrocytes was not significant. 
However, the increase in mRNA levels following culturing in -/- erythrocytes was 
slightly significant. 
 
 
 
Figure 3.18: Expression analyses of pfpdx1 and pfpdxk following growth in 
erythrocytes of the various genotypes.  The fold change in mRNA levels of pfpdx1 is 
shown on the left and that of pfpdxk on the right. The fold change in mRNA levels of both 
genes (Y axis) is plotted against the genotype of the erythrocytes used for culturing the 
parasites. Each measurement was carried out in duplicates (see material and methods 2.9). 
The mean and standard deviation was calculated as well as the p values. The data is 
representative of at least 3 independent experiments. Stars indicate a p value, ns stands for 
not significant. 
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3.6.1 Expression analyses of pfpdx1 and pfpdxk following culture in 
pyridoxine depleted medium  
 
I also investigated, if the absence of pyridoxine in the culture medium has an effect 
on the expression of the pfpdx1 and pfpdxk genes when the parasite is cultured in 
erythrocytes of the various genotypes. A 3D7 strain was cultured in erythrocytes of 
the various genotypes using pyridoxine depleted medium. I compared the mRNA 
levels of both genes of the parasite cultured in erythrocytes of the various genotype 
in pyridoxine depleted medium to levels following culturing in +/+ erythrocytes in the 
presence of pyridoxine (Fig 3.19) 
 
 
Figure 3.19: Expression analysis of pfpdx1 and pfpdxk after culturing parasites in 
pyridoxine depleted medium. The fold change in mRNA levels is shown for each genotype 
in pyridoxine depleted medium (-Pyr) and compared to that of the reference strain cultured in 
+/+ erythrocytes in the presence of pyridoxine (+Pyr). The measurements were carried out in 
duplicates (see material and methods 2.9) .The data for the pfpdx1 gene is representative for 
three independent experiments and the bars show the standard error. The mRNA level of the 
pfpdxk gene in pyridoxine depleted medium was measured only once and the columns stand 
for the mean of the duplicate measurements. 
 
I discovered an increase in mRNA levels for the pfpdx1 gene after the parasite was 
cultured in pyridoxine depleted medium using erythrocytes of the various genotypes. 
However it was not significant. The fold change in mRNA levels for the pfpdxk gene 
was relatively high with the highest increase in the -/- erythrocytes (30 fold) as 
compared to the mRNA levels of the reference strain which was cultured in +/+ 
erythrocytes in the presence of pyridoxine. 
 100
Results                  
 
 
There was also an increase in the mRNA levels of the pfpdx1 gene accompanying 
culture in pyridoxine depleted medium with erythrocytes of all various genotypes. I 
observed that this increase was highest when cultured in erythrocytes of the +/- 
genotype but this fold change was not significant. However, I observed a significant 
increase in the mRNA levels of pfpdx1 after culturing in erythrocytes of the +/+ 
genotype in pyridoxine depleted medium. 
  
3.7 PLP content of parasites cultured in erythrocytes of the 
various genotypes 
 
To determine the PLP content of the parasites when cultured in erythrocytes of the 
various genotype, a 3D7 strain was cultured in erythrocytes of the respective 
genotype for at least 4 weeks. I measured the PLP content of parasites that were 
cultured in +/+ and -/- erythrocytes in complete medium and of parasites that were 
cultured in +/+, +/- and -/- using pyridoxine depleted medium. Figure 3.20 shows the 
result of this experiment. I could not detect any difference in the PLP content of 
parasites after culturing in erythrocytes of the various genotypes. The absence of 
pyridoxine in the culture medium had no effect on the PLP content of the parasites. 
 
 
Figure 3.20: Parasitic PLP content.  The PLP content of parasites (Y-axis) cultured in 
erythrocytes of the different genotypes was determined. The parasites were cultured in RPMI 
1640 complete medium (+Pyr) or depleted of pyridoxine medium (-Pyr). There was no 
significant difference in the PLP content of the parasites. The error bars stand for the 
standard error of 3 independent measurements. 
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3.8 Erythrocyte deformability assay 
 
It has been shown that certain substances that act as antioxidant can affect the 
elasticity of erythrocytes. The elasticity of erythrocytes reflects their deformability. 
Substances like aminoguanidine, pyridoxyliden-aminoguanidine and pyridoxal had a 
positive influence on the elasticity of erythrocytes. This was assessed by the 
erythrocyte filterability in which pyridoxal exhibited the highest positive effect on the 
filterability of erythrocytes (Beder, Kittova et al. 2003; Mataseje, Beder et al. 2003). 
To elucidate if the lowered erythrocytic pyridoxal kinase activity has an effect on the 
deformability of erythrocytes bearing this polymorphism, I analysed the filterability of 
erythrocytes bearing the +/+, +/- and -/- genotypes as proposed by Mataseje et al., 
2003 (see material and methods 2.2.4). 
The hypothesis behind this experiment is that individuals bearing the +/+ genotype 
and therefore having normal erythrocytic PdxK activity should have a higher level of 
pyridoxal 5-phosphate which positively influences the deformability of the 
erythrocytes. It is consequently expected that erythrocytes of individuals bearing the 
+/+ genotype should have a higher elasticity reflected by a higher filtration rate than 
erythrocytes of the -/- genotype. 
 
 
 
 
3.8.1 Evaluating the method  
 
To demonstrate the feasibility of the method for this purpose, I decided to compare 
the filterability of freshly drawn uninfected erythrocytes to that of infected erythrocytes 
(figure 3.21).  As expected the filtration rate of uninfected fresh erythrocytes (50%) 
was significantly higher that of the infected erythrocytes (30%) (t test, p value: 0.009) 
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Figure 3.21: Proof of principle for the filterability method. The filtration rate, plotted on 
the Y axis of infected erythrocytes was lower than that of uninfected fresh erythrocytes. The 
data is representative for 3 independent experiments and proves that the method is 
sufficient. 
 
 
 
3.8.2 Filtration rate of erythrocytes bearing the +/+, +/- and -/-
genotype 
 
The filtration rates of freshly drawn erythrocytes bearing the +/+, +/- and -/- was 
determined.  I could not detect any significant differences in filtration rates among the 
various genotypes. I also determined the filtration rates of only infected erythrocytes 
bearing the various genotypes at a parasitemia of about 3% (see materials and 
methods) and I found no difference in filtration rates. 
 
 
Figure 3.22: filtration rates of infected and uninfected erythrocytes. The filtration rates of 
freshly drawn erythrocytes bearing the various genotypes were compared (left panel) and 
there was no significant difference found. The filtration rates of infected erythrocytes of the 
+/+, +/- and -/- genotypes was also compared by comparing the parasitemia after filtration to 
the parasitemia before filtration. Filtration rate: no of infected erythrocytes after centrifugation 
/ no of infected erythrocytes before centrifugation x 100. There was no difference detected. 
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Using the method as described by Mataseje A et al, I could not detect any difference 
in filtration rates of erythrocytes bearing the various genotypes which implies that the 
polymorphism has no effect on the deformability of the erythrocytes. It is also 
possible that no difference was found due to the limitation of the method. The method 
could detect differences in filtration rates when comparing infected erythrocytes from 
culture to freshly drawn erythrocytes. In this case a clear difference is expected. 
However, for the differences between the different genotypes, which are expected to 
be less pronounced, it is likely that the method is not sensitive enough. Other 
sophisticated more sensitive methods have been employed to measure the 
deformability of red blood cells (Park, 2008) and such methods might be a more 
appropriate approach for this analysis. 
 
 
 
 
 
 
 
3.9 Parasite morphology 
 
The in vitro growth assay experiment showed clearly that the growth of the parasite is 
impaired when cultured in erythrocytes from individuals bearing the -/- genotype. It is 
therefore possible that the morphology of the parasite is affected when cultivated in   
-/- erythrocytes. To elucidate if this is the case, the morphology of the parasites were 
scrutinized by light microscopy as well as electron microscopy. 
Giemsa stained slides of infected erythrocytes with the +/+ and -/- genotype were 
examined with a light microscopy. The erythrocytes of a given gentotype were 
infected with the FCR3 strain and the culture was held for at least 20 days. 
 
Light microscopical inspection of infected erythrocytes of the +/+ and -/- genotype did 
not result in the detection of any morphological alterations of the intracellular 
parasite. It appeared that the trophozoite stages of the parasite in +/+ erythrocytes in 
some cases looked slightly better than in -/- erythrocytes (Fig.3.23) 
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  To have a closer look at the morphology of the parasite when cultured in 
erythrocytes of the +/+ and -/- genotype, I also examined the parasites with electron 
microscopy. A 3D7 strain which has been cultivated in erythrocytes of the various 
genotypes for a period of at least 3 months was used for this experiment. The 
trophozoite stages were enriched with the MACS column, fixed, embedded, cryo-
sectioned and stained according to the method proposed by Tokuyasu for electron 
microscopy (Tokuyasu, 1980)  
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Figure 3.23: FCR3 strain in +/+ and -/- erythrocytes.  Blood smears of +/+ and -/- 
erythrocytes infected with the FCR3 strain were stained with Giemsa and examined by light 
microscopy. Left panel: FCR3 in +/+ erythrocytes, right panel: FCR 3 in -/- erythrocytes. 
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Figure 3.25: EM pictures of infected +/+ erythrocytes.  Erythrocytes of the +/+ genotype 
infected with the 3D7 strain was examined by electron microscopy. The bar represents 1 µm. 
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Figure 3.26: EM pictures of infected -/- erythrocytes.  -/- erythrocytes infected with a 3D7 
strain were imaged by electron microscopy. The bars represent 1 µm. 
 
 
 
Figure 3.25 shows EM pictures of sections of infected +/+ erythrocytes. The 
erythrocytes are infected with trophozoite and schizont stages of the parasite. The 
last picture shows merozoites of a schizont stage. Hemozoin, the malaria pigment 
which is a haemoglobin degradation product was easy to detect as crystals in the 
food vacuole and the parasitophorous vacuole membrane (PVM) was clearly 
distinguishable.  
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Figure 3.26 shows EM pictures of infected erythrocytes of the -/- genotype. The 
pictures show trophozoite stages. Hemozoin was also present and it was easy to 
identify the parasitophorous vacuole membrane. 
At a first glance the EM pictures showed that the parasites looked better in 
erythrocytes of +/+ erythrocyte but this could be based on the quality of the sections 
that were imaged.  I studied the EM pictures of infected erythrocytes of the two 
genotypes +/+ and -/- more closely and could not detect any clear differences in the 
over all morphology of the parasite.  
I did not observe any clear aberrant development of features like the parasitophorous 
vacuole membrane (PVM), membranes of inner compartments or hemozoin crystals 
of the parasite cultured in -/- erythrocytes. 
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4. Discussion 
 
The immense diseases burden of malaria on the world in particular on Sub-Saharan 
Africa, renders malaria the most important parasitic disease today. The control of this 
disease has been hampered by drug resistance in the Plasmodium parasite and by 
the lack of an effective vaccine. A better understanding of the pathogenesis of 
malaria, including the identification of innate or adaptive host defence mechanisms 
against blood stage parasite, may provide new targets for intervention of this disease. 
 
  The malaria parasite and its human host have co-evolved for a very long time and 
are permanently in interaction with each other. The parasite has various mechanisms 
to exploit its host cell thereby ensuring its survival and replication. The selective 
pressure of the parasite on its human host has resulted in selection of genetic 
polymorphisms which offer its carriers protection against malaria. The erythrocyte 
being the main spot for parasite infection and replication is also the main scene for 
genetic alterations that reduce the susceptibility to malaria infection (Min-Oo and 
Gros 2005; Williams 2006). This is one of the clearest evidences to suggest co-
evolution of the Plasmodium parasite and its human host in areas endemic for the 
disease. The role of host genetic factors conferring resistance to malaria was 
discovered half a century ago. Due to the complex nature of host-parasite interaction, 
the mechanisms of protection are still not fully understood (Kwiatkowski 2000). 
The haemoglobinopathies (α and β thalassaemia, HbAS, HbC, and HbE) are genetic 
polymorphisms that are well known to protect against malaria. Several studies have 
provided evidence for this assumption (Roberts and Williams 2003; Richer and 
Chudley 2005).  
  Genetic alterations of erythrocytic enzymes that affect susceptibility/resistance to 
malaria have also been observed. The most common one is the glucose 6-phosphate 
dehydrogenase (G6PD) deficiency which has been intensively studied (Bienzle, 
Ayeni et al. 1972; Cappadoro, Giribaldi et al. 1998; Guindo, Fairhurst et al. 2007). 
G6PD deficiency is linked to the X chromosome and over 300 variants of this trait 
have been reported. Recently, it has been reported that deficiency in the erythrocytic 
pyruvate kinase and gluthathione reductase is associated with reduced susceptibility 
to malaria. However, these two enzymopathies and their association with malaria 
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have not been intensively studied (Min-Oo, Fortin et al. 2003; Gallo, Schwarzer et al. 
2009). 
  In general, the alteration of erythrocytic enzyme affects the coding region of the 
respective gene. Most variants of G6PD causing enzyme deficiency also have altered 
biochemical properties and this is solely caused by point mutations affecting the 
coding sequence (Chang and Liu 1995; Mehta, Mason et al. 2000). Pyruvate kinase 
(PK) deficiency is the second most common erythrocyte enzyme disorder. More than 
130 different mutations, mostly missense, have so far been described in association 
with PK deficiency and are exclusively located in the coding region of the gene as 
well (Zanella and Bianchi 2000; Ayi, Min-Oo et al. 2008).  
  Pyridoxal kinase (PdxK) is involved in the metabolism of vitamin B6. Thirty years 
ago it was reported that the activity of the erythrocytic pyridoxal kinase is lowered in 
American blacks as compared to American whites and that lowered activity of the 
erythrocytic pyridoxal kinase in Africans is probably associated with resistance to 
malaria infection (Chern and Beutler 1976; Martin, Miller et al. 1978).  
In contrast to the above described enzyme disorders associated with malaria, genetic 
polymorphism at the erythrocytic pyridoxal kinase gene locus, seems to be the result 
of an insertion/deletion (In/Del) event in the promoter region of its gene. An 8 bp 
insertion in the pdxk promoter introduces a binding site for a putative core promoter 
binding protein (CPBP) that is known to enhance transcription. This insertion event 
has been postulated to result in an increase in PdxK activity in erythrocytes. This also 
suggests that the absence of the 8 bp insertion would lead to a lower activity of the 
enzyme. Flanagan and Beutler were able to show that individuals homozygous for 
the insertion indeed had a higher erythrocytic PdxK activity when compared to 
individuals without the insertion event (Flanagan and Beutler 2006). 
 
  In this thesis, I wanted to test the hypothesis that the lowered erythrocytic PdxK 
activity is another genetic trait offering protection against malaria by observing its 
effect on P. falciparum in an in vitro culture system. 
I developed two PCR based methods for the screening of human genomic DNA for 
the presence or absence of the 8 bp insertion in the promoter region of the pdxk 
gene. One was an allele specific PCR designed exclusively for the detection of the 8 
bp In /Del event which was required for this project. The second method was a PCR 
amplifying a small fragment of 80/88 bp around the region of the 8 bp In/Del event 
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and then detecting the difference in size on a 4 % metaphor gel (see material and 
methods 2.1). However this second PCR based method was not used for screening 
as it was difficult detecting the heterozygotes and this could lead to a 
misinterpretation of the results (see results 3.1). 
The result of the allele specific PCR screen was verified by sequencing and the 
method proved to be reliable. 
 
  Yet, sequencing the PCR fragments showed that there are other polymorphisms, 
e.g a second In/Del (see results) event of 7 bp,in the pdxk promoter region 130 bp 
upstream of the In/del event which has been previously reported (Flanagan and 
Beutler 2006).. Whether these additional polymorphisms which I observed, affect the 
transcription of the pdxk gene and whether they are under a selective pressure 
caused by malaria needs to be established. For this purpose, other more suitable 
PCR based methods need to be developed for their detection than the ones which 
have been used in this study. However, this was not the main focus of this project. 
 
  Screening genomic DNA of Caucasians and Africans for the presence (+/+) or 
absence (-/-) of the 8 bp in the pdxk promoter,  showed clearly that the 8 bp deletion 
event (-/-) which is associated with the lowered PdxK activity in erythrocytes is more 
prevalent among East Africans (malaria endemic) when compared to Caucasians (no 
malaria risk). The result of my PCR screen corresponded with the results of various 
population studies which have shown that genetic polymorphisms correlating with 
resistance to malaria are distributed among individuals in endemic regions (Cooke 
and Hill 2001; Craig, Hastings et al. 2001).  
 
  Since this project was carried out in Heidelberg, the blood of Caucasian donors was 
used for all investigations with Plasmodium falciparum. The advantage of using blood 
from Caucasians for the in vitro experiments is that the prevalence of other genetic 
factors that are known to reduce the susceptibility to malaria can almost be ruled out. 
Of the 42 Caucasians, which were screened for the polymorphism in the promoter of 
the pdxk gene, only 2 individuals were homozygous for the deletion event. 
Accordingly, all in vitro experiments were carried out with erythrocytes from these 
individuals.  Experiments conducted with erythrocytes from only 2 individuals bearing 
the deletion genotype (-/-) may be considered as not statistically relevant. It is 
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therefore recommended to conduct this study in an endemic region with a higher 
frequency of this genetic trait. This would increase the sample size for all in vitro 
experiments.  
 
  A number of promoter polymorphisms are known to affect the expression of the 
respective genes resulting in an increase or decrease in protein levels. It has been 
reported that two allelic variants of the interleukin 6 promoter (-572 and -174 G→C) 
influences the IL-6 activity both in vivo and in vitro. Another example is a genetic 
variation (1 bp In/del event) in the promoter of the human stromelysin-1 which 
influences the expression of the gene (Ye, Eriksson et al. 1996; Ferrari, Ahn-Luong et 
al. 2003).   
 
  Given that matured erythrocytes do not have mRNA, I examined whether the 
presence or absence of the 8 bp insertion in the pdxk promoter region affects 
transcription of the gene by analysing the protein level of the enzyme in erythrocytes 
by Western blot analysis. The protein level of PdxK was lower in erythrocytes of 
individuals bearing the deletion (-/-) genotype when compared to erythrocytes from 
individuals homozygous for the insertion (+/+).  
  To elucidate, if the protein level of the PdxK in erythrocytes of individuals bearing 
the various genotypes (+/+, +/- and -/-) correlates with the activity of the protein, I 
conducted enzyme activity assays. The amount of PLP formed after three hours of 
incubation with lysate of erythrocytes from various individuals correlated poorly with 
the different genotypes. However, the kinetics of the enzyme reaction showed that 
the amount of PLP formed per minute with lysate of the +/+ genotype (4.0 nmol/L) 
was significantly higher than that of the -/- genotype (2.5 nmol/L). This result clearly 
correlated with the amount of PdxK present in the individual lysate. It furthermore 
confirms the findings of Flanagan and Beutler which showed that the 8 bp insertion 
(+/+) resulted in an increased PdxK activity in erythrocytes and that the absence of 
the 8 bp insertion (-/-) had the opposite effect.  
 
  Quantification of the amount of PLP in erythrocytes of the various genotypes in 
culture showed that erythrocytes of the +/+ genotype in pyridoxine containing 
medium had the highest PLP content (286 nmol/L) reflecting the higher PdxK activity 
as compared to erythrocytes of the -/- genotype (118 nmol/L) The low level of PLP in 
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erythrocytes of the -/- genotype in the presence of pyridoxine can be explained by the 
lowered activity of the PdxK in these cells.  
The erythrocyte can only replenish its pool of vitamin B6 by taking up the vitamins, in 
this case pyridoxine from the culture medium (Ink and Henderson 1984; Anderson, 
Perry et al. 1989). In the absence of vitamin B6 in the medium, the exhausted pool of 
vitamin B6 in the erythrocytes cannot be replenished. Determining the PLP content of 
erythrocytes of the various genotype in the absence of pyridoxine confirmed this as 
the level of PLP (90.3 nmol/L in average) was significantly less than that of +/+ 
erythrocytes cultured in the presence of pyridoxine containing medium. 
 
  An important part of this project was to investigate the mechanism by which lowered 
erythrocytic PdxK may confer protection against malaria using an in vitro culture 
system.  
A high parasite density in the blood stream is considered to be one of the factors 
associated with severe malaria and the high replication rate with which parasites 
multiply in the bloodstream is also thought to increase the risk of progression to 
severe disease (Field 1949; Mockenhaupt, Ehrhardt et al. 2004). The majority of 
erythrocyte polymorphisms that are known to reduce susceptibility to malaria reduce 
parasite density. This has been illustrated by in vitro growth experiments. It has been 
shown that the parasite’s growth is impaired when cultured in erythrocytes from 
individuals bearing the HbAS, HbCC, HbEE and the G6PD deficiency trait as 
compared to controls. This effect is most pronounced in erythrocytes with the HbAS 
trait. Parasitemia was 10 times higher in HbAA erythrocytes than in HbAS or HbSS 
erythrocytes. In the case of the G6PD deficiency trait, parasitemia was about three 
times higher in normal erythrocytes than in G6PD deficient cells (Friedman 1978; 
Roth, Raventos-Suarez et al. 1983; Olson and Nagel 1986; Chotivanich, 
Udomsangpetch et al. 2002).  
 
  The result of my in vitro growth experiments showed that the growth of the parasite 
is impaired when cultured in erythrocytes from individuals bearing the -/- genotype as 
compared to individuals bearing the +/+ genotype. The parasitemia in -/- erythrocytes 
was about half that of +/+ erythrocytes. I also observed this retarded growth 
phenotype when using erythrocytes from two unrelated individuals bearing the 
deletion (-/-) genotype. In these growth experiments, the retarded growth phenotype 
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was first detected after 8 days of culture. One explanation for this apparent delayed 
onset of effect could be that at the beginning of the experiment, infected erythrocytes 
(genotype unknown) were added to uninfected erythrocytes of the respective 
genotype in a ratio of 1:10. Thus, at the beginning of the experiment 1/10 of the 
erythrocytes in culture were not of the respective genotype. Since the cultures were 
splitted every third day, eventually only erythrocytes of the respective genotype were 
present in the culture. On day 8, only 1/1000 of the erythrocytes present in the culture 
were not of the particular genotype. An indication that this indeed may be true comes 
from the short term growths experiments for which the parasites were cultured in 
erythrocytes of the various genotypes for a period of 4 weeks before the start of the 
experiment. I observed an instant impairment of the parasite’s growth in erythrocytes 
of the -/- genotype and an intermediate growth phenotype for most parasite strains in 
erythrocytes of the +/- genotype. This also mimics an in vivo situation where the 
parasites are confronted with only erythrocytes of the particular genotype. Moreover, 
the short term growth assays, which were performed for 3 days, showed that the 
impaired growth phenotype applies to P. falciparum strains with different drug 
resistance patterns, suggesting that the genetic trait affects all parasite strains 
regardless of their drug resistance background.  
Another explanation for the delayed impairment of growth in erythrocytes of the -/- 
genotype observed in the in vitro growth experiments, could be that the vitamin B6 
stores of the parasite were filled at the beginning of the experiment. In light of the 
quite long biological half life of vitamin B6, which is somewhat between 15 and 21 
days, one could imagine that there is a certain delay until the parasite is affected by 
pyridoxine depletion, even more since it is in part able to counterbalance the 
depletion by upregulation of PLP de novo biosynthesis (see results 3.6) 
 
  The results of the in vitro growth experiments suggest that in an in vivo situation the 
parasite density in the blood stream of individuals bearing the deletion genotype (-/-) 
is likely to be less than in individuals with the insertion genotype (+/+). This is 
consistent with what is known of other genetic alterations of the erythrocyte that 
reduce parasite infection and growth thereby reducing the risk of severe malaria 
(Hutagalung, Wilairatana et al. 1999; Aidoo, Terlouw et al. 2002; Mockenhaupt, 
Ehrhardt et al. 2004). Presumably, infections are most susceptible to resistance 
mechanism during bottlenecks of the Plasmodium life cycle. One of these bottlenecks 
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for blood stage parasites is the first replication cycle in red blood cells after the 
release of liver stage merozoites into the blood stream (Baer, Klotz et al. 2007). 
However, to exclude the possibility that the observed impaired growth phenotype of 
parasites cultured in erythrocytes of the -/- genotype is as a result of other genetic 
alterations, it is absolutely necessary to conduct these growth experiments with blood 
from more donors bearing the -/- genotype. 
 
  Comparing the parasitemia of cultures in the presence or absence of pyridoxine in 
the growth medium showed that the growth of the parasite is somewhat slower in the 
absence of pyridoxine regardless of the erythrocyte’s genotype. This effect was seen 
more clearly when the parasites were cultured in erythrocytes of the -/- genotype in 
the absence of pyridoxine. This implies that the parasite is affected by the limited 
resources of vitamin B6 in its erythrocytic environment. It has to be taken into 
consideration that although the parasites were cultured in pyridoxine depleted 
medium, a small amount of vitamin B6 is still brought into the culture system by the 
addition of fresh erythrocytes during the splitting of the culture. The amount of vitamin 
B6 brought into the culture by the addition of fresh erythrocytes is approximately 1.9 -
2.9 nmol/L. Bearing in mind that the half life of vitamin B6 is 15-21 days, vitamin B6 
was never totally absent in the culture as the culture was splitted every 3 days by the 
addition of fresh erythrocytes. 
 Yet the presence of pyridoxine in the culture medium would lead to a considerable 
increase in the erythroctyic pool of vitamin B6. Upon uptake into the erythrocyte, 
pyridoxine is phosphorylated by the pyridoxal kinase to PNP which is converted to 
PLP by the erythrocytic PNP oxidase. PLP and PNP can be dephosphorylated by the 
alkaline phosphotase to pyridoxal and pyridoxine which can then be taken up by the 
parasite (Ink and Henderson 1984). 
  The impaired growth of the parasite in pyridoxine depleted medium regardless of 
the genotype of the erythrocyte implies that the parasite needs to take up vitamin B6 
from the host erythrocyte to support maximal growth. The growth of the parasite 
within its host erythrocyte is dependent on the uptake of a number of essential 
nutrients from the extracellular medium. This has been shown by various studies 
demonstrating the supply of nutrients and disposal of waste products by the host cell 
(Huber, Uhlemann et al. 2002; Wrenger, Eschbach et al. 2006; Downie, Kirk et al. 
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2008). An example is the rapid uptake of pantothenate (vitamin A) by the parasite 
from the erythrocyte´s cytosol for its survival (Saliba, Horner et al. 1998). 
 
  Knowing that the parasite possesses a de novo biosynthesis pathway for pyridoxal 
5-phosphate, I investigated if lowered erythrocytic PdxK activity could have an effect 
on the parasitic vitamin B6 homeostasis. Analysis of the expression profile of pfpdx1 
which is involved in the de novo synthesis of PLP and of pfpdxk which is involved in 
the salvage of vitamin B6 by the parasite, showed that the mRNA levels of pfpdx1 
(2.5 fold) and pfdxk (2.0 fold) were increased when the parasite is cultured in 
erythrocytes bearing the deletion genotype (-/-) as compared to those cultured in 
erythrocytes of the insertion genotype (+/+). This data suggest that the parasite may 
respond to deficient B6 supply by upregulating compensatory mechanisms. This 
interpretation is supported by data showing that in the absence of pyridoxine, the 
mRNA levels of pfpdxk of parasites cultured in the erythrocytes of the diverse 
genotypes were much higher than in the presence of pyridoxine. This could imply that 
the parasite is desperately trying to salvage the limited resources of vitamin B6 in its 
environment.  
 
  It is known that during the blood stage development of the malaria parasite, the 
parasite takes up and degrades enormous amounts of haemoglobin from the host 
erythrocyte (Francis, Sullivan et al. 1997; Elliot 2008). Haemoglobin is digested in the 
acidic food vacuole of the parasite by proteinases. It also has been shown that 
pyridoxal 5-phosphate binds tightly to haemoglobin. PLP reacts with the N terminus 
of the β globin chain of haemoglobin via Schiff`s base formation (Benesch, Yung et 
al. 1973; Benesch, Benesch et al. 1982). Hydrolysis of haemoglobin bound PLP in 
the acidic food vacuole of the parasite would lead to the release of PL which can 
diffuse through the membrane of the food vacuole into the parasite’s cytosol. In the 
parasite´s cytosol, PL can be converted to PLP by the parasitic PdxK. 
It can be assumed that the amount of PLP bound to haemoglobin is higher in 
erythrocytes of the +/+ genotype than of the -/- genotype. This would also lead to the 
release of higher levels of PL into the parasitic cytosol upon uptake of haemoglobin 
bound PLP by the parasite in erythrocytes of the +/+ genotype as compared to 
erythrocytes of the -/- genotype. This implies that the parasite has a higher access to 
vitamin B6 from host erythrocytes of the +/+ genotype as compared to the -/- 
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genotype. This hypothesis is supported by the observed upregulation of the parasitic 
genes pfpdx1 and pfpdxK following culturing in erythrocytes of the -/- genotype. To 
test this assumption, the uptake of vitamin B6 by the parasite from the erythrocyte, 
should be investigated. This can be done by conducting uptake experiments with 
radioactive labelled (3H) pyridoxine (Ink, Mehansho et al. 1982). 
 
  In vitro growth experiments have shown that the growth of P. falciparum is impaired 
in G6PD deficient erythrocytes and this is due to oxidative stress imposed on the 
parasite (Roth, Raventos-Suarez et al. 1983; Guindo, Fairhurst et al. 2007). 
Furthermore, it has been shown that this impaired growth phenotype is abolished 
after two or three growth cycles of the parasite in G6PD deficient cells. There is 
evidence that the parasite can produce its own G6PD enzyme which may 
compensate for the deficient host G6PD enzyme and could account for the 
resumption of normal growth in G6PD deficient host cells. It has also been shown 
that the expression of P. falciparum antioxidant enzymes is enhanced when the 
parasite is cultured in G6PD deficient cells enabling the parasite to resist oxidative 
stress (Roth 1988; Akide-Ndunge, Tambini et al. 2009).These are examples of the 
capacity of the parasite to adapt to environmental changes.  
 
  In contrast, an upregulation of transcription of the pfpdx1 and pfpdxk genes, which 
are involved in maintaining the vitamin B6 homeostasis of the parasite, did not fully 
rescue the impaired growth phenotype when the parasites were cultured in 
erythrocytes bearing the -/- genotype with the reduced PdxK activity. This indicates 
that the parasite is not capable of totally overcoming the limited bioavailability of 
vitamin B6 in its environment. Measuring the amount of PLP in the parasite cultured 
in erythrocytes of the various genotypes in the presence or absence of pyridoxine 
showed no significant differences in the parasitic PLP levels. Even the roughly 30 fold 
upregulation of the parasitic PfPdxK expression did not lead to an increased parasitic 
level of PLP when the parasites were cultured in erythrocytes of the -/- genotype. 
This suggests that there is a kind of optimal PLP concentration which is sensed by 
the parasite. 
 
  My observations in this work support the hypothesis that the lowered erythrocytic 
PdxK activity could be a genetic trait that reduces the susceptibility to malaria 
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infection. However, the mechanism of protection remains unclear. In an attempt to 
elucidate the mechanism behind the protective effect of this trait, I decided to 
evaluate the effect of reduced PdxK activity on the deformability of the erythrocyte. 
The extreme deformability of erythrocytes allows the red blood cells with a diameter 
of 8 µM to pass trough a 4 µM capillary lumen. Aged, abnormal or damaged 
erythrocytes have an altered membrane cytoskeleton, which results in loss of 
deformability.  Erythrocytes with a more rigid membrane cytoskeleton get stuck in the 
sinusoids of the spleen, where they are selectively removed by spleen macrophages 
(Bennett and Kay 1981).  
During its intraerythrocytic development, the parasite causes structural, biochemical 
and mechanical changes in the erythrocyte, which results in a loss of erythrocyte 
deformability (Park, Diez-Silva et al. 2008). Furthermore, the parasite exerts oxidative 
stress on the host erythrocyte, which can also lead to a loss in membrane flexibility 
(Hunt 1990) Thus, infected erythrocytes become more rigid and are therefore 
removed from circulation in the spleen (Dondorp 1999). Erythrocyte polymorphisms 
such as the sickle cell trait and α,β thalassaemia have been linked with reduced 
erythrocyte deformability (Dondorp 1999).  However it is not clear if this could also 
play a role in the mechanism of their protective effects against malaria infection. 
Southeast Asian ovalocytosis is also associated with reduced red blood cell 
deformability and this has been shown to inhibit invasion of the parasites (Jarolim 
1991; Genton 1995). 
Conversely, membrane active substances with antioxidative properties can positively 
influence the erythrocyte deformability. Pyridoxal is an antioxidative substance and it 
has been reported that pyridoxal positively influences the elasticity of the erythrocyte 
membrane (Beder, Kittova et al. 2003). Given that the lowered erythrocytic PdxK 
activity would lead to lower PLP levels in the erythrocyte of the -/- genotype, it is 
assumed that infected erythrocytes of the -/- genotype could be less deformable than 
those of the +/+ erythrocytes. This would also suggest that infected erythrocytes of 
the -/- genotype are more likely to be selectively removed from the circulation by the 
spleen than those of the +/+ genotype. 
  However, the investigation of the deformability of infected and uninfected 
erythrocytes of the various genotypes using the filtration method (Mataseje, Beder et 
al. 2003) revealed no differences in the filterability of the erythrocytes. This suggests 
that erythrocytes of the -/- genotype do not exhibit a reduced deformability as 
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compared to those of the +/+ genotype. In order to rule out the limitation of the 
method used for the assay as the cause of the obtained results, further investigations 
with more precise and detailed methods may be required (Nash 1989; Dondorp 1999; 
Dondorp 1999; Park 2008). 
 
  A number of studies have shown that some genetic traits affecting the erythrocyte 
impair the growth of the parasite in vitro. Yet, not much is known about the 
morphology of the parasite during its development in erythrocytes with these genetic 
variants. One study conducted by Fairhurst et al. illustrated abnormal development of 
the parasite in HbCC cells and linked it to the reduced multiplication rates of the 
parasite in HbCC cells. In this study the parasites were examined with light 
microscopy and electron microscopy. Electron microscopy of the parasite showed 
that the intracellular compartments were lost when the parasite was cultured in HbCC 
cells (see figure 4.1) (Fairhurst, Fujioka et al. 2003). 
 
 
 
Figure 4.1: Abnormal morphology of the parasite in HbCC erythrocytes. B: Parasite in 
HbAA erythrocytes, C and E: Parasite in HbCC erythrocytes. The bar stands for 1µm. Figure 
were taken from Fairhurst et al. (Fairhurst, Fujioka et al. 2003). 
 
 
It has been reported that vitamin B6 and its derivates are sufficient singlet oxygen 
quenchers and potential antioxidants (Ehrenshaft, Bilski et al. 1999; Bilski, Li et al. 
2000). This led to the assumption that erythrocytes of the +/+ genotype containing 
higher levels of PLP would provide a more conducive redox environment for the 
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parasite than erythrocytes of the -/- genotype. The parasite in the -/- erythrocyte is 
therefore likely to be exposed to increased oxidative stress when compared to the 
+/+ genotype. One of the main features of oxidative stress in cells is membrane 
damage due to phospholipid oxidation (Sies 1997; Pradines 2005) and this is 
escorted by abnormal morphology of the cells. 
 I examined the morphology of the parasites cultured in -/- erythrocytes with light 
microscopy and for more details with electron microscopy. For electron microscopy 
the method as proposed by Tokuyasu was used. This method is ideal for the 
preservation of membrane structures during fixation (Tokuyasu 1980; Geiger B 
1981).  
Although light microscopy of Giemsa stained parasites showed that some  
trophozoite stages cultured in -/- erythrocytes looked unusual as compared to those 
cultured in +/+ erythrocytes, a closer examination with electron microscopy showed 
no clear differences in the morphology of the parasites. The membranes were intact 
in both cases and intracellular compartments were present. A failure to establish the 
parasitophorous vacuole, intracellular compartments and membranes in erythrocytes 
of the -/- genotype can consequently be ruled out as the cause of impaired growth of 
the parasites in erythrocytes with lowered PdxK activity. 
 
 
 
4.1 Conclusions 
    
  Early studies on the lowered erythrocytic PdxK activity in blacks and its possible role 
in protection against malaria allowed for the hypothesis that this could be a trait which 
reduces the susceptibility of the human host to malaria. For over thirty years no 
additional investigations were carried out to prove this hypothesis. The relatively 
recent discovery of the genetic basis for the reduced PdxK activity in erythrocytes 
enables the screening of individuals for this polymorphism followed by in vitro studies 
to investigate the effect of this trait on P. falciparum. 
  Screening Africans and Caucasians showed that the 8 bp deletion in the promoter 
region of the pdxk gene which is associated with the lowered activity of the enzyme in 
erythrocytes is more prevalent among Africans in agreement with the geographical 
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distribution of red blood cell polymorphisms that protect against malaria (Cooke and 
Hill 2001). The lower protein level of PdxK in erythrocytes of the deletion genotype -/- 
suggests that the reduced activity of the erythrocytic PdxK is strictly associated with 
low protein levels. This is also supported by the lower PLP level measured in 
erythrocytes of the -/- genotype. The impaired growth phenotype of the parasite in 
erythrocytes of the -/- genotype shows that the lowered erythrocytic PdxK activity has 
an in vitro effect on P. falciparum. Although the parasitic de novo or salvage 
pathways for vitamin B6 were upregulated in the -/- genotype by roughly 2-3 fold, 
upregulation could not counterbalance this phenotype. Figure 4.2 illustrates a 
hypothetical model demonstrating the effect of this genetic trait on the blood stages 
of P. falciparum. 
  In summary, my data provide a plausible explanation for the previously observed 
association between lowered erythrocytic PdxK activity and the risk of malaria. 
infection. It also suggests directions for further research such as investigating the in 
vivo effect of this erythrocytic alteration on the clinical outcome of malaria. Population 
studies correlating this polymorphism in the pdxk promoter with the susceptibility to 
malaria in endemic regions are therefore highly recommended. 
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Figure 4.2:  Influence of the 8 bp deletion on the P. falciparum blood stages 
This hypothetical model demonstrates the effect of the 8 bp deletion in the promoter of the 
pdxk gene on P. falciparum.  Data supporting the events in the grey box could not be 
generated in this project. This part of the model is based on facts derived from published 
data A: The presence of the 8 bp insertion leads to a higher PdxK activity in erythrocytes 
which is accompanied by higher levels of PLP. PLP binds to haemoglobin. Haemoglobin with 
a higher percentage of bound PLP is taken up by the parasite. In the parasite´s acidic food 
vacuole, PLP is released from haemoglobin and is hydrolysed to PL which can exit the food 
vacuole. High levels of PL are therefore released into the parasite´s cytosol and 
phosphorylated by the parasitic PdxK. The parasite has a sufficient supply of PLP and 
matures and replicates normally. 
B: The absence of the 8 bp insertion in the promoter of the pdxk gene leads to a lower PdxK 
activity in erythrocyte resulting in lower levels of PLP. Haemoglobin with a lower percentage 
of bound PLP is taken up by the parasite and the level of PL available for the parasite is thus 
reduced. The parasite is not capable of fully compensating for the decreased resources of 
vitamin B6 in the -/- genotype environment and this could affect its development in the 
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erythrocyte resulting in a reduced parasitemia. A reduction in parasitemia could be as a 
result of reduced invasion, reduced merozoite formation or a prolonged intraerythrocytic 
development. 
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